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ABSTRACT OF DISSERTATION 
 
 
 
 
 
EFFECTS OF ADIPOGENIC COMPOUNDS ON GROWTH PERFORMANCE, 
HORMONAL STATUS AND FAT DEPOSITION OF FINISHING BEEF STEERS 
 
 Processes that regulate site of fat deposition in beef cattle are poorly understood.  
For the producer to procure the greatest profit, it is ideal to maximize intramuscular fat.  
Furthermore, to understand the physiological mechanisms affecting fat depots, it is 
necessary to evaluate hormones involved in growth regulation.  Using a 2 x 2 factorial 
design of treatments, four experiments were conducted to examine two adipogenic 
compounds, chlortetracycline and dexamethasone.  Synovex-S® and Revalor-S® were 
used to investigate potential interactions between growth implants and adipogenic 
compound.  Growth performance, carcass quality, organ and fat mass and plasma 
hormone concentrations were measured in these studies. 
 
 In Exp. 1, 24 steers received either 0 or 350mg chlortetracycline/d, with or 
without Synovex-S®.  On d 30, 56 and 106, steers received a bolus injection of 1 ug/kg 
BW thyrotropin-releasing hormone and 0.1 ug/kg BW GH-releasing hormone and serial 
blood samples were collected.  Synovex-S® increased (P ≤ 0.009) rate and efficiency of 
gain and decreased (P = 0.05) time to peak for GH concentrations.  Chlortetracycline 
attenuated (P ≤ 0.05) the effects of implant on triiodothyronine release, slaughter weight 
and carcass quality.  In Exp. 2, 96 steers received either 0 or 39.6 ppm 
chlortetracycline/d, with or without Revalor-S®.  Implant increased (P < 0.0001) ADG; 
however, efficiency of gain was greater for implanted steers in the absence of 
chlortetracycline (interaction, P ≤ 0.03). 
 
In Exp. 3, 144 steers received either 0 or 0.09 mg dexamethasone/kg BW on d 0, 
28 or 56, with or without Revalor-S®.  Average daily gain was lower (P = 0.0003) for 
implanted steers receiving dexamethasone compared to those receiving no 
dexamethasone (interaction, P = 0.05).  Omental fat mass was greater (P = 0.01) for 
non-implanted steers receiving dexamethasone compared to no dexamethasone 
(interaction, P = 0.006).  In Exp. 4, 96 steers received either 0 or 0.09 mg 
dexamethasone/kg BW on d 0, 28, 56 or 84, with or without Revalor-S®.  Average 
daily gain and efficiency of gain were both 13% greater (P ≤ 0.05) with implant.  
Conversely, DEX lowered ADG by 10% (P = 0.007).  There were no effects of 
treatment on fat mass weights. 
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Chapter 1 
Introduction 
 Although fat deposition has been studied extensively in ruminants, the 
mechanisms controlling this process remain poorly understood.  The effect of breeds of 
cattle (Charles and Johnson, 1976; Cianzio et al., 1982) and nutrition (Gill et al., 1993) on 
the amount of subcutaneous fat (backfat) and intramuscular fat (marbling) has been well 
documented.  In the 1950’s, livestock production in the United States shifted from 
animals raised on small, family farms and fed grass to large, intensive production systems 
in which animals were managed according to physiological stage and fed diets intended 
to maximize growth performance.  For cattle, this shift meant a change from pasture to 
feedlot finishing, where cattle were kept in large groups and grain was the primary feed 
source.  This diet change maximized weight gain in a short period; however, it also 
increased the percentage of gain associated with fat (Smith et al., 1984; Jones et al., 
1985).  It is generally accepted that 10-12 mm of backfat indicates that the animal is 
ready for slaughter, as marbling will likely be sufficient for the animal to grade Choice 
(Block et al., 2001).  However, an excess amount of backfat or visceral fat represents an 
economic loss, as these fat depots are not part of the usable carcass, while greater 
amounts of intramuscular fat, or marbling, increase the value of the carcass.    Yet, it is 
not clear why this increase in intramuscular fat occurs. 
Type II diabetes research has helped to elucidate some of the cellular mechanisms 
involved in visceral and intramuscular fat deposition in humans and rats (Bonora 2000; 
Hegarty et al., 2002).  While sites of lipogenesis and fatty acid precursors differ between 
humans and ruminants, it is possible that some similarities exist regarding changes in fat 
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deposition when diets high in carbohydrates are consumed.  When humans consume 
carbohydrates and fat in excess of daily energy requirements, they usually become obese, 
and as a result could become Type II diabetic and insulin resistant (Kahn et al., 2006).  
Insulin resistance is a physiological state in which tissues such as subcutaneous fat and 
muscle become resistant to insulin.  Cells in these depots have stored the maximum 
amount of triglyceride and it is hypothesized that they are capable of storing no more 
lipid droplets (Frayn 2001).  Therefore, lipid deposition shifts from subcutaneous and 
visceral sites to intramuscular sites.  This shift has been well-documented in humans; 
however, it has not been documented in beef cattle. 
 While a shift in fat deposition due to obesity in beef cattle has not been 
documented, research regarding the addition of particular compounds to beef cattle diets 
for the enhancement of intramuscular fat has been conducted.  In particular, feeding 
chlortetracycline (CTC) at subtherapeutic levels (350 mg/steer/d) has been shown to 
increase marbling in growing steers fed for 91 d (Rumsey et al., 2000).  While the 
mechanism by which CTC accomplishes this increase in marbling is unclear, there are 
some indications that it is achieved through changes in hormones released from the 
anterior pituitary, namely growth hormone (GH) and thyroid-stimulating hormone (TSH; 
Rumsey et al., 1999). 
 Another compound which has been widely used in human and rat models to study 
insulin resistance and changes in fat deposition is the synthetic glucocorticoid, 
dexamethasone.  It has been found that one-time or frequent doses of dexamethasone 
induce temporary insulin resistance, as indicated by a glucose challenge and changes in 
plasma insulin concentrations (Matsumoto et al., 1996; Severino et al., 2002; Nicod et al., 
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2003; Binnert et al., 2004).  Furthermore, frequent, long-term doses of dexamethasone 
have caused a semi-permanent state of insulin resistance; administration of 
dexamethasone over long periods of time also generates other adverse side-effects 
commonly associated with glucocorticoids, such as compromised immunity, increased 
blood pressure and lowered threshold for seizure (Veterinary Drug Handbook, 1999).  
While it is possible for these negative side effects to occur, the use of dexamethasone in 
research offers an opportunity to study the physiological changes associated with insulin 
resistance and fat deposition as they relate to Type II diabetes.  Particularly, it may be 
possible to use dexamethasone to study changes in fat deposition in beef cattle. 
 Although, dexamethasone has been used to a limited degree in ruminants, its 
effect on intramuscular fat deposition has been significant.  For example, in one study 
dexamethasone has been used in sheep for the improvement of feed intake and body 
weight gain (Adams and Sanders, 1992).  In another, the use of intramuscular injections 
of dexamethasone in beef cattle at several intervals prior to slaughter and found 
improvements in the number of cattle grading Choice (Brethour 1972).  This research 
provided an additional model for studying ways to manipulate intramuscular fat in beef 
cattle. 
 Therefore, the two main goals of the research discussed in this dissertation were 
to 1) investigate the effects of CTC and dexamethasone on the amount of intramuscular 
fat in beef cattle and 2) determine if CTC and dexamethasone interacted with hormonal 
growth implants to affect overall weight gain and the amount of intramuscular fat. 
 
Copyright © Susanna E. Kitts 2011 
4 
 
Chapter 2 
Literature Review 
Physiological control and mechanisms of fat deposition in ruminants 
In today’s society, body fat generally has negative connotations and viewed as 
unhealthy.  If present in excess, harmful conditions such as diabetes are inclined to 
develop.  However, adipose tissue has great physiological significance and provides 
benefits in mammals which are often overlooked.  Fat imparts insulation for humans or 
other mammals living in cold environments, provides energy and vitamin storage, and 
produces cytokines, which have a role in inflammation.   
Dietary lipid supply 
 Fat is a very efficient form in which energy is stored, and is vital for the 
production of prostaglandins, thromboxanes and leukotrienes, as well as for cell 
membrane structure.  Triglyceride synthesis requires either a dietary source of a specific 
fatty acid or synthesis of fatty acids within the body.  Furthermore, dietary substrates 
such as carbohydrate or fat can greatly affect triglyceride synthesis.  In humans, both 
carbohydrate and fat are consumed in roughly equal proportions; however, in general, 
ruminants ingest more carbohydrate and less fat.  Also, fat is digested differently in 
ruminants because of the rumen; therefore, it is necessary to understand this process in 
order to appreciate how the proportion of precursors for triglyceride synthesis is different 
in ruminants. 
 Cattle on pasture consume mostly structural lipids such as phospholipids or 
galactolipids (≤ 50%; Church, 1988).  In a feedlot situation, cattle may consume more 
grain and oil seeds, which contain most of the lipid as storage lipid or triglycerides (65-
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80%; Church, 1988).  In both settings, ruminal metabolism allows no oxidation of lipid in 
the rumen, as it is an anaerobic environment (Church, 1988).  Many of the lipids entering 
the rumen are polyunsaturated and bacteria use polyunsaturated fat to dispose of excess 
hydrogen atoms in a process called biohydrogenation (Church, 1988; Bauchart et al., 
1996).   
 There are three types of lipid which can pass from the rumen to the small 
intestine: unaltered, dietary lipid after hydrogenation by ruminal microbes, and microbial 
lipid (Church, 1988).  Because of these differences, fat entering the small intestine bears 
little resemblance to the fat ingested in the diet.  Most of the fat tends to be highly 
saturated, which ruminants are able to digest to a higher degree than non-ruminants 
(Church, 1988). 
Digestion and absorption of fat in ruminants 
 In ruminants, the digesta entering the small intestine is very acidic, which 
negatively affects the solubility of fat and bile acids (Church, 1988).  Bile and pancreatic 
juice emulsify fat entering the small intestine (Church, 1988; Bauchart et al., 1996), and 
pancreatic secretions contain high amounts of bicarbonate, promote an increase in pH.  
Because of the acidity of the duodenum, most hydrolysis of triglycerides begins to occur 
in the mid-jejunum at a slightly higher pH, also the site at which fatty acids are 
solubilized and converted to micelles by bile acids. (Church, 1988).  Only about 20% of 
fatty acids are absorbed in the proximal jejunum, with the remainder absorbed in the mid- 
and distal jejunum. 
 Once fatty acids are formed into micelles, they diffuse into the villous cell where 
re-esterification occurs in the membrane of the smooth endoplasmic reticulum (Church, 
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1988).  The re-esterified fatty acids are packaged with either tri-, di-, or mono-glycerides, 
phosphlipid, cholesterol and apoproteins to form chylomicrons that exit into the 
intercellular space (Church, 1988).  Chylomicrons diffuse through gaps in the basement 
membrane to the lamina propria and enter the lymph system (Church, 1988).  In 
ruminants, chylomicrons are generallyprevalent when unsaturated fatty acids are 
presented to the small intestine, while very low density lipoproteins (VLDL) are 
predominantwhen high amounst of saturated fat are fed (Church, 1988; Bauchart et al., 
1996).   
Transport of fat 
 While fatty acids with a chain length less than C14 can enter the blood directly, 
most lipids are transported by the lymph system as chylomicrons and VLDL (Church, 
1988).  A small amount of lipid can also be present in the blood as low (LDL) or high 
(HDL) density lipoproteins or non-esterified fatty acids (NEFA) associated with albumin 
(Church, 1988).  Once chylomicrons and VLDL enter the plasma, a component 
associated with apoprotein C activates lipoprotein lipase, which is present on the surface 
of endothelial cells lining the capillary walls of capillaries in skeletal muscle, adipose and 
mammary tissue (Church, 1988).  This hydrolysis allows fatty acids to be taken up by 
tissue for oxidation or synthesis of triglycerides. 
Triglyceride synthesis 
 Unlike non-ruminants, synthesis of fatty acids is minimal in the liver of 
ruminants.  Almost 100% of de novo lipogenesis occurs in the adipose tissue of 
ruminants (Ingle et al., 1972).  In general, the precursors for fatty acid synthesis in 
ruminants differ from that of non-ruminants (Ingle et al., 1972).  While the main 
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precursor for acetyl-CoA in non-ruminants is glucose, in ruminants, acetate is the main 
substrate due to fermentation in the rumen (Ingle et al., 1972), although a considerable 
amount of glucose is available to the small intestine when ruminants are fed high 
concentrate diets (Harmon and McLeod, 2001).  A study by Hanson and Ballard (1967) 
sought to determine the contribution of glucose and acetate to lipogenesis in the adipose 
tissue of sheep and cattle.  Mesenteric adipose tissue was incubated with either glucose or 
acetate and the conversion of each substrate to fatty acid measured.  It was determined 
that the incorporation of acetate into the mesenteric adipose tissue of sheep and cattle was 
212% and 266% greater, respectively, than the incorporation of glucose.  While this data 
shows a preference for acetate as a substrate for lipogenesis in mesenteric adipose tissue, 
other research has demonstrated that the precursors used for lipogenesis in ruminants also 
appear to be site-dependent.  Research by Smith and Crouse (1984) evaluated the relative 
contributions of acetate and glucose as carbon precursors for fatty acid synthesis in 
intramuscular and subcutaneous adipose tissue obtained from 16-month old Angus steers.  
It was found that acetate supplied 70-80% of the acetyl units for lipogenesis in 
subcutaneous adipose tissue and only 10-25% in intramuscular adipose tissue.  However, 
glucose provided 50-75% of the acetyl units in intramuscular fat and only 1-10% in the 
subcutaneous depot.  While acetate is the main lipogenetic substrate for ruminants, this 
study shows that lipogenic substrates can differ based on the location of adipose depots.  
 Ruminant diets normally have a moderate effect on the composition of adipose 
tissue because of ruminal hydrogenation.  However, feeding poly-unsaturated fatty acids 
in excess of the capacity of the rumen for hydrogenation can allow some fat to escape to 
the small intestine for absorption (Church 1988).  In this case, triglyceride synthesis in 
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adipose tissue will reflect the composition of the unsaturated fatty acids absorbed.  If a 
high-concentrate diet is fed, a shift towards greater propionate production will occur in 
the rumen (Church 1988, Bergman, 1990).  However, despite the greater production of 
propionate, acetate still constitute at least 50% of the VFA produced (Bergman, 1990).  
Additionally, up to 20% of starch intake in high-concentrate diets can bypass ruminal 
fermentation and enter the small intestine for digestion to glucose (Huntington 1997).  
Therefore, a high-concentrate diet ultimately provides acetate, propionate and glucose as 
lipogenic precursors.  Acetate can be taken up by adipose tissue and used to form acetyl-
CoA for fatty acid synthesis.  Propionate is removed from the portal blood by the liver, as 
it is the major substrate for gluconeogenesis in ruminants (Coleman et al., 1995).  Finally, 
glucose absorbed by the small intestine from both bypass starch and glucose produced 
from propionate can also be used to form acetyl-CoA.  However, in ruminants glucose is 
essential for glycerol formation, as they cannot convert glycerol 3-phosphate to glycerol 
(Vernon and Flint, 1988). 
Fat deposition and maturity 
 Cattle producers and feedlots constantly manipulate the growth of cattle to change 
nutrient partitioning and feed-conversion efficiency.  The strategies employed attempt to 
increase muscle tissue deposition at the expense of adipose tissue growth.  This approach 
contradicts the natural physiology of the animal.  Both muscle and adipose tissue rank 
relatively low in priority in the body’s allocation of nutrients compared with bone, 
lymphoid and neural tissue, as well as gut maintenance (Wray-Cahen et al., 1998).  
However, to manipulate growth processes successfully, it is helpful to understand the 
growth and development of cattle. 
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 All muscle tissue develops from the proliferation and differentiation of satellite 
cells.  Some of the growth factors that play major roles in the regulation of muscle 
growth include the insulin-like growth factors (IGFs), fibroblast growth factors (FGFs), 
and transforming growth factor-β (TGF-β; Wray-Cahen et al., 1998).  Regardless of diet 
composition, lean tissue accretion has a higher priority than adipose tissue in the young, 
growing animal (Hammond 1952).  Furthermore, with increasing maturity, the rate of 
protein growth decreases (Byers, 1982; Owens et al., 1995).  To maximize lean tissue 
gain for cattle in the latter stages of the finishing period, it is a common practice to 
implant these cattle with a growth promotant containing combinations of estrogen or 
trenbolone acetate plus progesterone to repartition nutrients. 
 As cattle grow and once they reach mature weight, excess available energy is 
retained as fat.  Thus, total fat composes a higher percentage of body weight gain with 
increasing maturity and days on feed.  There are at least 5 primary fat depots and 1 
secondary fat depot in the ruminant animal.  The primary fat depots consist of omental, 
mesenteric, subcutaneous, intermuscular and kidney, pelvic and heart fat (KPH; Charles 
and Johnson, 1976).  The secondary fat depot of major interest is intramuscular fat, i.e., 
marbling.  While it is preferable that the amount of fat in the omental, mesenteric and 
KPH fat depots is low to reduce non-carcass weight, the amount of intramuscular fat 
should be high to improve quality grade and thus, increase profit.  
Although there may be differences in fat distribution between the frame sizes of 
steers as they mature, there is a similar pattern of fat deposition. Cianzio et al. (1982) 
compared the adiposity of steers of small and large frame size from 11 to 19 mo of age.  
The smaller framed steers showed an earlier increase in the rate of fat deposition from 11 
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to 13 mo of age.  Interestingly, as fattening proceeded the growth rate of pelvic and 
mesenteric fat decreased in the large frame steers; however, with the exception of pelvic 
fat, all fat depots (subcutaneous, intermuscular, kidney, omental, mesenteric) increased at 
the same rate in the small frame steers.  However, intramuscular fat increased at a rate 
similar to that of total fat in both frame sizes, demonstrating that this depot is not the last 
type of lipid to be deposited.  These findings contradict other work which suggests that 
intramuscular fat is the last fat depot to develop (Hammond, 1955; Hood and Allen, 
1973; Vernon et al., 2001). 
 In another study which evaluated fat distribution in the carcass, Johnson et al. 
(1972) also showed that intramuscular fat did not increase with fattening.  Rather, the 
authors hypothesized that the expression of intramuscular fat is late maturing.  These 
studies demonstrate that overall, fat deposition increases at a steady rate throughout the 
growing and finishing periods.  However, as protein accretion decreases later in the 
finishing period, fat assumes a greater proportion of weight gain.  At this point, the 
amount of intramuscular fat present becomes of great importance because of its proximity 
to slaughter time. While some research suggests that intramuscular fat increases 
throughout growth, the rate at which it is deposited may be affected by a myriad of other 
factors such as genetics, growth history and type of diet (Cianzio et al., 1982).  It is 
possible that the high concentrate diets fed to finishing cattle may cause insulin 
resistance, which in turn may increase the amount of intramuscular fat.   These 
possibilities will be explored in depth in a later section of this review. 
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Effects of chlortetracycline and dexamethasone on fat deposition in ruminants and 
non-ruminants 
 
General effects of antibiotics in livestock 
 It has been demonstrated for some time that the addition of antibiotics to livestock 
feed improves growth performance.  Some of the common additives include 
chlortetracycline, oxytetracycline, penicillin, bacitracin, streptomycin, tylosin and 
oleandomycin (Wallace, 1970).  While some of these additives may be used more in 
some species than others, they all share a common characteristic of suppressing or 
inhibiting the growth of microorganisms.  Controlling the outbreak of disease caused by 
microorganisms became especially important in the 1950’s with the development of 
confinement rearing of food animals in large flocks and herds (Gustafson and Bowen, 
1997).  Although it is not entirely clear how these antibiotics improve growth 
performance, there are theories which propose metabolic, nutrient-sparing and disease 
control effects (Wallace, 1970).   While it seems that activity against Gram-positive 
bacteria is important for swine and poultry, any further mechanisms of action by 
antibiotics in non-ruminants is unclear (Gustafson and Bowen, 1997). 
 In ruminants, ionophore antibiotics have been shown to be very effective in 
altering energy utilization by shifting acetate and butyrate production to propionate, as 
well as improving feed efficiency (Richardson et al., 1976; Bergen and Bates, 1984).  
Additionally, antiobiotics have routinely been used as prophylactics to protect entire 
herds or flocks of animals at risk for disease.  This is especially true of young cattle that 
have traveled long distances, as they are at risk for respiratory disease caused by 
Pasteurella haemolytica or P. multocida (Gustafson and Bowen, 1997).  These animals 
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are under extreme stress and many feedlot workers dose with a broad spectrum antibiotic 
feed additive to prevent reduced growth performance and death.  Antiobiotics are 
effective in improving growth and feed efficiency; however, specific antiobiotics such as 
chlortetracycline (CTC) have been shown not only to increase growth and efficiency of 
feed utilization, but to improve carcass quality as well (Bohman et al., 1957; Landagora 
et al., 1957; Perry et al., 1958; Heinemann and Fanelli, 1963; Rumsey et al., 2000). 
Chlortetracycline, growth performance and carcass quality in ruminants 
 Historically, CTC has been fed to beef steers, dairy calves and sheep with 
differing effects on average daily gain, efficiency of weight gain and carcass 
characteristics.  Most experiments have shown an increase in average daily gain for beef 
steers and dairy calves (Bohman et al., 1957; Landagora et al., 1957; Perry et al., 1958; 
Heinemann and Fanelli 1963).  In an experiment by Landagora et al. (1957), 54 dairy 
calves received either the basal ration, 50-75 mg CTC/d in milk or 400 mg CTC HCl/d 
intramuscularly.  While there was no difference in weight gain between the calves 
administered CTC orally or intramuscularly, calves treated with CTC gained 0.1 kg 
BW/d more than calves given only a basal ration.  A study by Perry et al. (1958) 
demonstrated that steers fed 80 mg CTC/d gained 5.4% more than steers receiving no 
CTC.  In another experiment, steers fed for an average of 77 d received either 0 or 75 mg 
CTC/d (Heinemann and Fanelli, 1963).  The steers fed CTC gained 0.28 kg more than the 
steers fed no CTC.  Burroughs et al. (1959) summarized the results of 112 experiments 
involving the feeding of subtherapeutic levels of antibiotics to cattle and found that CTC 
increased ADG by 4% over animals receiving no CTC.  However, a study by Harvey et 
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al. (1968) showed no improvements in ADG for steers fed 75 mg CTC/d for an average 
of 175 d.   
 Similar to ADG, the effects of CTC on efficiency of BW gain has been variable in 
cattle, especially during the finishing phase.  In a growing and finishing experiment by 
Heinemann and Fanelli (1963), steers receiving 75 mg/d chlortetracycline had more 
efficient weight gain compared to steers fed no chlortetracycline.  Likewise, Perry et al. 
(1954) observed an increase of 18% in feed efficiency when chlortetracycline was fed at 
a rate of 75 mg/d.  However, many studies have shown chlortetracycline to have no effect 
on efficiency of weight gain (Neumann et al., 1951; Bohman et al., 1957; Rumsey et al., 
2000; Kitts et al., 2006).  While the cause of varying responses to CTC in these 
experiments is unclear, it has been suggested that the effects of CTC on growth 
performance are more apparent under stressful conditions that are more immunologically 
challenging to the animal (Visek 1978).  Thus, it is possible that the benefits of CTC 
observed in younger animals are due to the suppression of non-beneficial bacteria which 
sometimes proliferate under conditions of stress, such as weaning or transport. 
 Most of the data regarding the effects of CTC on carcass quality has shown 
limited or no improvement (Bohman et al., 1957; Landagora et al., 1957; Bohman and 
Wade, 1958; Heinemann and Fanelli, 1963; Rumsey et al., 2000; Kitts et al., 2006).  In an 
experiment by Bohman et al. (1957), 48 steers (351 kg) were fed 0 or 70 mg/d CTC for 
either 119 or 126 d.  Evaluation of carcass grade and dressing percentage revealed no 
effect of CTC.  In another study by Bohman and Wade (1958), 48 steers (~2 yr old) were 
fed 0 or 70 mg/d CTC for 120 d and the percentage of separable fat in the 9-10-11 rib cut 
was determined.  Chlortetracycline did not change the percentage of separable fat.  
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Heinemann and Fanelli (1963) used 72 steers (299 kg) receiving a supplement of 75 mg/d 
of CTC for either 84 or 97 d.  At slaughter, steers were evaluated for grade, thickness of 
the round and chuck, loin area, and fat cover at the 12th rib.  These carcass characteristics 
were not affected by CTC.  A later study by Kitts et al. (2006) used 96 steers (401 kg) fed 
either 0 or 39.6 ppm/d CTC for either 126 or 140 d.  There was no effect of CTC on 
longissimus area, longissimus fat cover, KPH fat, marbling or yield grade. 
Conversely, two experiments have shown oral CTC to have limited improvements in 
carcass quality and increased carcass fat deposition.  Landagora et al. (1957) used 54 
newborn Jersey and Holstein calves that were slaughtered at 12 or 16 weeks of age.  The 
control group received the basal ration, the second group was fed 50-75 mg/d CTC, and 
the third group received an intramuscular injection of 400 mg/d CTC HCl.  There were 
no differences in measurements between calves fed or injected with CTC; however, 
calves fed or receiving injections had heavier carcass weights, higher dressing 
percentages, increased size and weight of round and rib cuts, and higher meat yields.  In 
another experiment by Rumsey et al. (2000), thirty-two steers (286 kg) were fed CTC 
(350 mg/d) for 91 d and then slaughtered.  Chlortetracycline increased longissimus fat 
cover and tended to increase slaughter weight and marbling.  It is notable that the 
experiments in which carcass quality and fat deposition were improved used younger 
animals and higher dosage levels of CTC per unit BW.  It is possible that CTC is not 
effective in older animals, such as those used in the previous experiments. 
Chlortetracycline, growth performance and carcass quality in non-ruminants 
  In general, CTC has been shown to improve growth performance and carcass 
quality in non-ruminants, such as swine and poultry.  In an experiment by Hill and 
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Larson (1955), 81 baby pigs obtained by hysterectomy were fed a milk diet and half of 
the pigs were supplemented with 10 ppm/d CTC for 24 d.  Pigs were then fed solid feed 
for 56 d and received 200 ppm/d CTC.  During the initial period, pigs receiving CTC 
gained 11% more BW than the control animals.  Likewise, pigs receiving CTC during the 
second period gained 16% more BW relative to the control animals.  Chlortetracycline 
clearly improved growth performance of suckling and weanling pigs in this experiment.        
In another study by Braham et al. (1958), chicks and rats were used to determine 
the effects of several antibiotics, including CTC, on weight gain.  One hundred twenty 
chicks were fed two levels of 5 different antibiotics, including CTC, for 4 weeks.  Chicks 
received 0, 10, or 1000 mg/kg diet penicillin, CTC, novobiocin, zinc bacitracin or 
streptomycin.  Chicks receiving 1000 mg/kg CTC weighed 31% more after 4 weeks 
relative to chicks receiving no antibiotic.  There was no effect on weight gain for chicks 
fed 10 mg/kg CTC after 4 weeks.  In this same experiment, 60 male albino rats were fed 
0 or 1000 mg/kg diet penicillin, CTC, novobiocin, zinc bacitracin or streptomycin for 4 
weeks.  Rats receiving CTC gained 38% more BW compared to rats fed no CTC.  
Clearly, CTC enhanced weight gain in both growing chicks and rats when fed at high 
levels. 
Few studies have shown substantial improvements in carcass quality of non-
ruminants fed CTC; furthermore, most research regarding the effects of CTC on carcass 
quality has been limited to swine.  An experiment by Kelly et al. (1957) evaluated 48 
weanling pigs (13 kg) divided into two groups of 24 pigs each.  From each group, six 
pigs were removed at 39, 57, 75, and 93 kg BW for slaughter.  The first group received a 
basal ration and the second group received the basal ration plus 22 ppt/d CTC.  There 
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were no effects of CTC on the carcass composition or quality of pigs slaughtered at 57, 
75, or 93 kg BW; however, barrows receiving CTC and slaughtered at 39 kg BW had 
14% more fat in the carcass relative to barrows receiving no CTC.  Furthermore, these 
barrows had greater backfat thickness compared to barrows fed no CTC.  Another study 
by Wallace et al. (1955) evaluated the influence of CTC on growth and carcass quality of 
pigs fed restricted rations.  A total of 110 weanlings pigs (19.9 kg) were used in 3 
experiments, one in drylot and two in pasture.  In each experiment, rations were fed as 
unrestricted, allowed 80% of feed consumed by the unrestricted group, or allowed 60% 
of feed consumed by the unrestricted group.  These treatments were repeated and 
supplemented with CTC (20g/ton).  Pigs were slaughtered when they reached a finished 
weight of 86 kg.  In Exp.1, the unrestricted group that received CTC had the highest 
dressing percentage, but no effect when feed intake was controlled.  There were no 
effects of CTC on carcass characteristics in Exp. 2 or 3.  These studies indicate few 
effects of CTC on carcass quality. 
Effects of chlortetracycline on pituitary and thyroid hormones 
 Little research has been done related to the effects of CTC on hormones released 
from the pituitary and thyroid glands.  Early research had suggested the positive growth 
effects of CTC to be attributed to its antimicrobial actions (Gustafson and Bowen, 1997).  
However, it is has been hypothesized that CTC affects growth via an endocrine axis 
(Landagora et al. 1957).  This idea is supported by a study performed by Hsu et al. 
(1970).  Chicks were fed a basal ration containing no CTC, basal ration plus 25 ppm 
untreated CTC or basal ration plus 1 ppm decomposed CTC.  After 4 weeks, the chicks 
were evaluated for growth and thyroid histology and function.  It was observed that 
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chicks receiving the untreated CTC gained more body weight than chicks fed the basal 
ration or basal ration plus decomposed CTC.  Examination of the thyroid glands of the 
chicks fed untreated CTC showed stimulation of growth due to hypertrophy and 
hyperplasia.  These data supported the theory that the positive effects of CTC on growth 
may be due to effects on an endocrine axis involving the thyroid gland and not due solely 
to antimicrobial effects.   
Growth hormone (GH) and thyroid-stimulating hormone (TSH) released from the 
pituitary gland, and triiodothyronine (T3) and thyroxine (T4) released from the thyroid 
gland, have significant roles in the growth and metabolism of animals (Larsen 2003).  A 
primary function of GH is to mediate growth through an increase in protein synthesis 
(Owens et al., 1993).  This increase in protein synthesis takes place at the expense of fat 
synthesis.  Therefore, it has been suggested that the increase in fat deposition observed 
with the administration of CTC may be a result of decreased synthesis or release of GH 
(Rumsey et al., 1999).   
Thyroid hormones (T3 and T4) play major roles in energy metabolism, acting to 
increase basal metabolic rate, promote protein synthesis, and stimulate fat mobilization 
via lipolysis (Sokoloff et al., 1968; Thenen and Carr, 1980).  The stimulation of fat 
mobilization leads to increased plasma fatty acid concentrations in plasma and oxidation 
of fatty acids by tissues.  Because it has been observed that CTC increases fat deposition, 
it would be expected that circulating concentrations of thyroid hormones would decrease.  
Rumsey et al. (1999) used 32 steers (285 kg) fed either a 10 or 13% CP diet and either a 
corn meal carrier or carrier + 350 mg CTC daily.  After 56 d, steers were injected with 
1.0 ug/kg BW TRH + 0.1 ug/kg BW GHRH and blood samples collected for 360 min 
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after releasing hormone injection.  Chlortetracycline decreased the amount of GH 
released from the pituitary and over time, decreased circulating TSH and T4.  This study 
also evaluated the effects of CTC on insulin-like growth factor-1 (IGF-1; McLeod et al., 
2003).  IGF-1 is a hormone with growth promoting effects and most tissues in the body 
possess receptors for IGF-1.  IGF-1 is produced primarily by the liver in response to GH 
(Davey et al., 2001).  It is also synthesized and released in target tissues in a 
paracrine/autocrine fashion (Adams 2002).  In the study by McLeod et al. (2003), blood 
was collected on d 0, 7, 14, 28, 56 and 84 prior to feeding and analyzed for IGF-1.  Over 
the entire experiment, circulating IGF-1 concentrations were unaffected by CTC.  
However, there was a tendency for steers receiving 10% protein + CTC to have lower 
IGF-1 concentrations on d 7 and 14 compared to steers receiving 13% protein. 
General physiological effects of glucocorticoids 
 A variety of steroids are synthesized from cholesterol in the adrenal cortex, 
including glucocorticoids, aldosterone and androgens.  These steroids are released into 
the circulation and have numerous effects on intermediary metabolism.  
Theglucocorticoidsare produced mainly in the zonae fasciulata and zonae reticularis 
layers of the adrenal gland (Veterinary Pharmacology and Therapeutics, 1995).  In most 
mammals, the major glucocorticoid is cortisol; however, in rats, the major glucocorticoid 
is corticosterone.  Cortisol is synthesized from cholesterol and released into circulation 
under the influence of adrenocorticotropic hormone (ACTH; Larsen 2003).  In humans, 
cortisol is secreted in response to pulsatile ACTH release with diurnal variation; 
however, studies have not confirmed diurnal variation in species such as the ruminant 
(Alila-Johansson et al., 2003; Hudson et al., 1975). 
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Glucocorticoids have effects on virtually all cell types and almost every 
physiological system in mammals.  In the cardiovascular system, glucocorticoids reduce 
capillary permeability and enhance vasoconstriction, thereby increasing blood pressure 
(Veterinary Drug Handbook, 1999).  In the nervous system, glucocorticoids can stimulate 
appetite, lower seizure threshold and alter behavior.  While glucocorticoids normally 
suppress release of endogenous corticosteroids, some conditions such as liver disease or 
diabetes may abolish suppression by glucocorticoids (Veterinary Drug Handbook, 1999).  
Additionally, release of TSH, follicle-stimulating hormone, prolactin and luteinizing 
hormone may be reduced when glucocorticoids are administered.  The conversion of T4 
to T3 may be reduced and insulin binding to insulin receptors may be inhibited by 
glucocorticoids (Veterinary Drug Handbook, 1999).  Glucocorticoids can suppress the 
immune system by decreasing production of lymphocytes, monocytes and eosinophils.   
Glucocorticoids have an antagonistic effect to that of insulin, leading to increased 
glucose production from amino acids and reduced incorporation of amino acids into 
protein (Veterinary Pharmacology and Therapeutics, 1995).  While glucocorticoids 
enhance lipolysis in the abdominal/visceral areas, pharmacological amounts can  result in 
insulin resistance and Type II diabetes, ultimately causing redistribution of fat to muscle 
(Amatruda et al., 1985; Lewis et al., 2002).  It is likely that this redistribution occurs 
because glucocorticoids stimulate appetite, causing hyperinsulinemia, which results in 
lipogenesis and ultimately obesity. (Veterinary Pharmacology and Therapeutics, 1995).  
As a result, diabetes mellitus may develop from prolonged glucocorticoid use at high 
dosage levels. 
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Dexamethasone 
Specifically, dexamethasone (DEX) is a synthetic glucocorticoid which acts as an 
anti-inflammatory agent and immunosuppressant.  While many of the effects of DEX are 
similar to those of the naturally occurring hormone, cortisol, its effects are 20-30 times 
more potent than those of hydrocortisone.  It is also considered to be a “long-acting” 
glucocorticoid (duration of action › 48 h; Veterinary Pharmacology and Therapeutics, 
1995).   
 While glucocorticoids have been used to treat specific conditions, they obviously 
have a myriad of effects on all systems of the body.  Therefore, many adverse effects can 
occur with long-term use of these drugs, especially with high dosage levels.  A few of 
these effects include growth retardation in young animals, dull, dry haircoats, weight 
gain, diarrhea, pancreatitis, lipidemias, diabetes mellitus, muscle wasting and behavioral 
changes (Veterinary Drug Handbook, 1999).  Despite these negative side effects, 
glucocorticoids such as DEX have been used extensively in research experiments, 
particularly to study glucose metabolism in both animals and humans (Plested et al., 
1987; Vernon and Taylor, 1988; Matsumoto et al., 1996; Schneiter and Tappy, 1998). 
Effects of dexamethasone on glucose metabolism 
A study by Schneiter and Tappy (1998) evaluated the effects of administration of 
DEX on the metabolism of an oral glucose load.  Six human volunteers (71.6 ± 2.8 kg) 
received 2 mg/d DEX in 4 doses (0.5 mg/dose) over a 2-d period.  On the morning of the 
glucose tolerance test, the volunteers received 1 mg DEX and ingested 75 g of [U-13C] 
glucose.  The 2-d treatment with DEX elevated circulating blood glucose over the control 
subjects who received no DEX.  Also, plasma insulin was approximately 400 pmol/L 
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higher in individuals receiving DEX compared to those receiving no DEX.  These results 
suggest that glucose tolerance is impaired with chronic administration of DEX. 
In another experiment by Matsumoto et al. (1996), twenty human volunteers were 
used to examine the dose-dependent effects of DEX on glucose tolerance.  Ten subjects 
received a low dose of DEX (2 mg/d) for 3 d, and the other ten received a high dose of 
DEX (6 mg/d) for 3 d.  Each subject underwent anintravenous glucose tolerance test 
before and after DEX administration.  In that study, glucose tolerance was impaired to a 
greater extent in the individuals who received the high-dose of DEX relative to those 
receiving the low-dose.  Additionally, individuals receiving both the high and low doses 
of DEX had higher plasma insulin levels compared to those receiving no DEX.  These 
results suggest that glucose tolerance is impaired in a dose-dependent manner when DEX 
is administered.  Vernon and Taylor (1988) conducted a study in lactating and non-
lactating sheep to determine the effects of DEX on control of glucose metabolism in 
adipose tissue.  Adipose tissues samples were obtained from lactating and non-lactating 
sheep and DEX added to a final concentration of 0, 0.1, 1, 10 or 100 nM.  It was observed 
that increasing concentrations of DEX decreased glucose uptake by adipocytes in both 
the lactating and non-lactating sheep.    In another study by Buren et al. (2002), rat 
adipocytes were isolated from epididymal fat pads and incubated for 24 h in the absence 
or presence of DEX at 0.3 µmol/L and insulin (104 µU/mL).  The cells were then washed 
and incubated with various insulin concentrations (0-1000 µU/mL) and D-[U-14C] 
glucose.  Glucose uptake was terminated after 1 h and cell-associated radioactivity 
determined.  It was found that the addition of DEX during the 24 h prior to the glucose 
uptake assay decreased both basal and insulin-stimulated glucose uptake by 40-50% 
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compared with the control cells.  The results of these studies show that DEX inhibits 
glucose uptake and utilization in the adipocytes of both sheep and rats. 
Effects of dexamethasone on adipogenesis and adipocyte differentiation 
 While DEX has been shown to inhibit glucose uptake and utilization in 
adipocytes, the effects of DEX on fatty acid synthesis are less clear.  Some research in 
humans has suggested that insulin-stimulated fatty acid synthesis in adipose tissue is 
inhibited when DEX is administered (Cigolini and Smith, 1979).  However, most recent 
research suggests that DEX stimulates fatty acid synthesis in both mice and humans 
(Dolinsky et al., 2004; Gounarides et al., 2008; Wang et al., 2004).  In an experiment by 
Dolinsky et al. (2004), mice were injected for 4 d with 40 mg/kg BW DEX and killed 24 
h after the final injection.  The mice receiving DEX had 2-fold higher plasma 
triacylglycerol (TAG) concentrations compared to mice receiving no DEX.  
Diacylglycerol acyltransferase (DGAT) is an enzyme that catalyzes the final stage of 
TAG synthesis; the expression of this enzyme was evaluated in the livers of mice injected 
with DEX and found to be increased at least 1.5-fold compared to mice given no DEX.  
In the study by Wang et al. (2004), subcutaneous fat was obtained from the abdominal 
region of non-obese, non-diabetic women and cultured with either no hormone (control), 
with insulin alone or with insulin plus DEX.  After 5 days of culture, fatty acid synthase 
(FAS) gene expression was evaluated.  Insulin enhanced mRNA abundance of the FAS 
gene 14-fold and insulin plus DEX enhanced FAS mRNA abundance 100-fold.  In 
another study by Goundarides et al. (2008), male mice were maintained on a high-fat diet 
for 2 months prior to receiving 3 intraperitoneal injections of 11 mg/kg DEX over a 5-d 
period.  At least 3 d before DEX injections and on d 8 following the last DEX dose, fat 
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distribution was determined by magnetic resonance imaging.  Relative to body weight, 
the results showed visceral fat to be 50% greater in the mice injected with DEX.  These 
studies clearly indicate that DEX stimulates fatty acid synthesis in the liver, subcutaneous 
and visceral fat depots.  In the liver and subcutaneous adipose depot, the increase in fatty 
acid synthesis is accomplished by increasing expression of various enzymes involved the 
fatty acid synthetic pathways. 
The effects of DEX on adipocyte differentiation are also vague; some research 
suggests that DEX inhibits a specific stage of adipocyte differentiation (Pairault and 
Lasnier, 1987), while most indicates that DEX promotes adipogenesis through adipocyte 
differentiation (Lepar and Jump, 1992; Smas et al., 1999; Zilberfarb et al., 2001).  The 
three stages of differentiation for preadipocytes include determination, commitment and 
terminal differentiation (Pairault and Lasnier, 1987; Gregoire et al., 1998).  Preadipose 
cell lines such as 3T3-F442A are already committed to the adipocyte lineage and are 
commonly used to study the progression of preadipocytes into terminal differentiation; 
however, entrance into the differentiation stage as well as the rate of differentiation can 
be manipulated based on the use of inhibitory or inducing agents (Gregoire et al., 1998).  
The most common inducing agents used for adipocyte differentiation include insulin and 
DEX, while retinoic acid has been shown to prevent differentiation (Pairault and Lasnier, 
1987). 
In a study by Pairault and Lasnier (1987), the effects of retinoic acid, DEX and 
insulin on terminal differentiation were evaluated in 3T3-F442A preadipocytes.  The 
programming of 3T3-F442A preadipocytes for differentiation takes place at confluence 
when cells stop their growth.  At this point, culture medium is supplemented with 
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effectors to be tested for the differentiation process.  The 3T3-F442A cells were grown to 
confluence and allowed to differentiate in the presence of insulin for 10 d.  At d 0, 2, 4, 6 
and 8, either retinoic acid, DEX or retinoic acid plus DEX were added to the cell culture.  
On d 11, the cells were prepared for enzyme extraction of glycerophosphate 
dehydrogenase (G3PDH), an enzyme with specific activity induced during adipocyte 
differentiation.  The inhibitory effect of DEX on differentiation was overcome by the 
presence of insulin.  When retinoic acid was added to the cells on d 0, G3PDH activity 
was essentially zero, increasing slowly until d 10.  However, the addition of retinoic acid 
and DEX strongly inhibited the expression of G3PDH, thus preventing differentiation.  
These results suggest that retinoic acid plus DEX prevent preadipocyte differentiation 
that cannot be reversed in the presence of insulin.  However, the presence of insulin 
reverses the inhibition of differentiation by DEX, but it is unable to reverse inhibition by 
retinoic acid. 
A study by Zilberfarb et al. (2001) evaluated the effects of DEX on TNF-α 
expression and adipocyte differentiation.  TNF-α expression has been shown to increase 
in obesity and insulin resistance and is an inhibitor of adipocyte differentiation (Stephens 
and Pekala, 1992; Hotamisligil and Spiegelman, 1994).  Human preadipocytes (PAZ6 
cells) from infant perirenal adipose tissue were cultured to confluence and supplemented 
with DEX and insulin or insulin alone.  In the absence of DEX, the expression of 
adipocyte markers such as insulin sensitive glucose transporter (GLUT-4), hormone 
sensitive lipase (HSL) and lipoprotein lipase (LPL) was barely detectable, suggesting that 
DEX is necessary for adipocyte differentiation.  The expression of TNF-α was reduced in 
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the presence of DEX, suggesting that the positive effect of DEX on adipocyte 
differentiation is mediated by the inhibition of TNF-α. 
Use of dexamethasone in ruminants 
 The main uses of DEX in cattle are for the treatment of arthritis, nerve damage 
and ketosis (Veterinary Drug Handbook, 1999).  However, some studies have 
investigated the effects of DEX on feed intake and body weight changes in sheep and 
effects on the amount of intramuscular fat in cattle (Brethour 1972; Adams and Sanders, 
1992).  Research by Adams and Sanders (1992) investigated the use of DEX to improve 
feed intake and reduce body weight loss in sheep moved inside animal houses or into 
feedlots.  Wethers injected with DEX at the time of introduction into the animal house ate 
more and lost less weight than untreated sheep within the first 24 h and over a 10-d 
period.  In the feedlot situation, sheep treated with DEX gained more weight than 
untreated sheep after 5 d.  These results suggest that a single injection of DEX helps to 
improve feed intake and reduce weight loss associated with movement of animals to a 
new environment. 
 Another study by Brethour (1972) was conducted in response to the observation 
that foundered cattle treated with DEX tended to have higher carcass grades.  Cattle with 
an average weight of 364 kg were injected IM with 10 mg of DEX 132, 90, 76 or 33 d 
prior to slaughter.  When cattle were injected with DEX 90, 76 or 33 d prior to slaughter, 
marbling score, a measure of intramuscular fat, was improved.  These results certainly 
suggest that single injections of DEX have the potential to increase intramuscular fat, 
thus increasing carcass value and producer profit. 
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Effects of anabolic steroids on tissue deposition in ruminants 
Anabolic steroids 
 Anabolic steroids have been administered to beef cattle for several decades to 
enhance growth rate and lean tissue deposition.  The use of steroids has provided an 
economic advantage for beef cattle producers, as enhancing growth rate can reduce the 
cost of producing meat.  Additionally, lean tissue deposition is preferred by producers 
over fat deposition, as more muscle increases the value of the carcass (McKenna et al., 
2002).  An increase in lean tissue deposition is generally accomplished at the expense of 
fat and requires altering the animal’s endocrine system (Buttery and Dawson, 1990).  
Several anabolic steroids have been developed to improve the growth of ruminants and 
these steroids are based on natural sex steroids.  Some of these include estradiol, estradiol 
benzoate plus progesterone, estradiol benzoate plus testosterone, zeranol and trenbolone 
acetate (Buttery and Dawson, 1990).  Most anabolic steroids are administered to steers or 
heifers as an ear implant sometime after weaning to increase growth rate and lean tissue 
deposition. 
Nutrient partitioning 
 Nutrient partitioning refers to the processes by which available nutrients are 
channeled in varying proportions to different metabolic functions (Friggens and 
Newbold, 2007).  Nutrients such as glucose or amino acids may be shuttled to tissues 
such as vital organs, muscle, adipose tissue or in the case of the dairy cow, milk.  The 
priority for conducting nutrients to different tissues is determined by the energy status of 
the animal; specifically, maintenance needs of the vital organs first must be met, then 
nutrients will be used for growth in young animals.  Regarding beef cattle, nutrient 
27 
 
partitioning becomes an important consideration for producers during the growth period 
after weaning, as it is crucial to increase growth rate, maximize lean tissue deposition and 
minimize adipose tissue as the animals approach “market weight,” the point at which they 
are utilized for meat (Mitchell 2007).  Excess adipose tissue in the form of backfat 
(subcutaneous fat) or visceral fat is unable to be utilized and considered an economic 
loss; therefore, the ability to manipulate nutrient partitioning via nutritional approaches or 
anabolic steroids has provided an economic benefit for producers (Trenkle and Marple, 
1983: Mitchell 2007). 
 Many factors control nutrient partitioning, particularly energy status, genetics, 
physiological state, and environment.  All of these elements can interact in a complex 
manner to determine the destination of nutrients at any given time.  It is now a common 
practice to use anabolic steroids to manipulate nutrient partitioning and especially in the 
case of cattle with less than optimal genetics, maximize lean tissue deposition.  The most 
common mechanisms by which anabolic agents repartition nutrients towards lean tissue 
include alterations in endogenous hormone levels, alterations in enzyme activity 
associated with protein turnover, and reductions in protein turnover (Lemieux et al., 
1985; Sinnett-Smith et al., 1983). 
 As an animal approaches maturity, body composition changes due to variation in 
growth rate of different organs and tissues.  In terms of growth of a young animal, the 
brain grows first, followed by bone, skeletal muscle and adipose tissue (Beitz 1985).  As 
the animal grows, protein and fat accretion occur simultaneously; however, as the animal 
approaches maturity, the rate of protein accretion decreases and fat accretion continues 
(Beitz 1985).  In order to change this scenario in favor of continued protein accretion 
28 
 
during different periods of growth, Lemieux et al. (1990) used 45 steers either not 
implanted or implanted at 90-d intervals with Ralgro® or Synovex-S®.  The animals 
were evaluated for body composition using deuterium oxide dilution during a 100-d 
growing phase and a 136-d finishing phase.    During the growing phase, protein gain 
increased an average of 26.5 g/d for the implanted steers compared to the non-implanted 
steers.  Fat gain decreased by 78% for the implanted vs. non-implanted steers.  During the 
finishing phase, protein gain for implanted and non-implanted steers was similar to that 
of the growing phase; however, fat gain was decreased for the implanted steers by only 
9%, as compared to the non-implanted steers.  When the relationship between daily 
protein gain and daily empty body gain was evaluated, it was determined that between 
the growth and finishing phases, daily protein gain at any rate of gain decreased for all 
implant groups.  This decrease reflects a lower priority for protein growth during the 
finishing phase.  However, during the finishing phase, cattle implanted with either 
Ralgro® or Synovex® still deposited protein at greater rates than non-implanted cattle.  
These results indicate that both Ralgro® (zeranol) and Synovex® (estrogen) repartition 
nutrients from fat to protein deposition during both the growing and finishing phases in 
cattle. 
Mechanism of action of growth implants – Synovex 
 Synovex® growth implants are anabolic steroids manufactured by Fort Dodge 
Animal Health in Overland, KS.  Synovex® includes a series of implants for calves, 
heifers and steers which are based on natural sex steroids.  This series includes estradiol 
benzoate plus progesterone (Synovex®C and Synovex®S) and testosterone propionate 
plus estradiol benzoate (Synovex®H).  These growth implants have been shown to 
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increase growth rate by 8-15% and feed conversion efficiency by 5-10% (Buttery and 
Dawson, 1990). 
 Research has shown that estrogen affects growth through the somatotropic axis; 
specifically it can increase the release of growth hormone (GH), which helps to regulate 
growth and development (Leung et al., 2004).  The regulatory mechanism of estrogen on 
GH occurs via secretion, clearance and action (Leung et al., 2004).  In humans, oral 
estrogen administration to postmenopausal women has been shown to increase circulating 
GH levels, thereby restoring normal GH secretion (Dawson-Hughes et al., 1986).  Some 
of the functions of GH include growth of skeletal muscle through increased protein 
synthesis, as well as stimulation of lipid oxidation and resting energy expenditure (Leung 
et al., 2004; Moller et al., 1990).  Another study performed in vitro with pituitary glands 
isolated from cycling female rats sought to determine the effects of estrogen on growth 
hormone synthesis and storage (Childs et al., 2005).  When pituitary cells were incubated 
with estrogen concentrations ranging from 0.01-10 nM, the percentage of GH antigen-
bearing cells increased.  Pituitary cells were also stimulated with analogs of GHRH and it 
was found that estrogen increased the number of cells with GHRH receptors.  These 
results support the positive effect of estrogen on GH production. 
 In cattle, an increase in GH secretion by the administration of an estrogen growth 
implant is beneficial in stimulating protein synthesis and subsequent lean tissue 
deposition.  Loy et al. (1988) used Charolais-crossbred steers receiving either no implant, 
implanted initially and on d 84 with Ralgro® (zeranol), or implanted initially and on d 84 
with Synovex-S® (progesterone plus estradiol benzoate).  On d 94, steers received a 
pituitary challenge, which consisted of a thyrotropin releasing hormone (TRH) injection.  
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Blood samples collected at 15 and 20 min post-challenge showed greater integrated areas 
above the GH level at time of TRH injection for both implanted groups of steers 
compared to non-implanted steers.  Additionally, the pituitary glands of the steers were 
removed at slaughter, weighed and analyzed for GH content.  The weights of the pituitary 
glands for both groups of implanted steers were 49% heavier compared to the non-
implanted steers.  Likewise, the pituitary glands of the implanted steers contained 20% 
more GH than the glands of the non-implanted steers.  These data demonstrated not only 
a greater GH content in the pituitary glands of steers receiving Synovex-S®, but a greater 
release of GH immediately following a TRH challenge. 
 Other research by Gopinath and Kitts (1984a) evaluated the effects of Synovex-
S® implants on GH secretion and clearance rates in growing beef steers.  To determine 
GH secretion and clearance rates, twelve growing Hereford beef steers were used.  Six 
steers were non-implanted controls and six received Synovex-S® implants at the base of 
the ear (200 mg progesterone and 20 mg estradiol benzoate).  Two steers from each 
treatment were chosen randomly to study GH kinetics.  Blood samples were collected at 
30 min intervals for 3.5 h to establish basal GH concentrations.  The steers were then 
injected with 6 mg bovine GH and serial blood samples collected at 5 min intervals for 50 
min and then at 60, 90 and 120 min following GH challenge.  Plasma basal GH 
concentrations were increased in the implanted compared to non-implanted steers.  Also, 
the disappearance of GH after the challenge was determined to occur in a biexponential 
fashion over a period of 120 min.  There was an initial rapid phase lasting 5 min and a 
slow disappearance phase lasting 42 min.  During the initial rapid phase, the implanted 
steers demonstrated an increased half-life of GH of 3.2 min relative to the control steers.  
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The secretion rate of GH was also found to be increased in the implanted steers when 
compared to the control steers.  These results demonstrate that circulating basal 
concentrations, secretion rate and half-life of GH are increased with estrogenic growth 
implants in growing beef steers. 
 The thyroid hormones triiodothyronine and thyroxine (T3 and T4, respectively) 
are important regulators of basal metabolic rate and protein synthesis (Welle and Nair, 
1990).  Thyroid hormone synthesis and release from the thyroid gland is stimulated by 
thyroid-stimulating hormone (TSH), which is produced and released by the anterior 
pituitary gland.  In turn, the release of TSH is controlled by thyrotropin-releasing 
hormone, which is released from the hypothalamus.  Research has shown estrogen to 
have pronounced effects on thyroid hormone metabolism.  Estrogen has been shown to 
increase the capacity of T4 binding to thyroxine-binding globulin (TBG) in plasma, 
decrease basal metabolic rate, increase release of TSH from the pituitary and increase 
thyroid activity (Engbring and Engstrom, 1959).  A study by Engbring and Engstrom 
(1959) in which human athyrotic patients received estrogen and adequate T4 replacement 
therapy showed an increase in the half-life of T4 from 6.9 to 10.6 d.  Another experiment 
by Dowling et. al (1960) supports a decrease in the fractional rate of turnover of T4 from 
plasma.  The results from these studies suggest that with estrogen administration, 
circulating T4 levels remain high for a longer period of time, thus increasing the 
availability of T4 for conversion to T3 in the peripheral tissues. 
 Another study by Lima et. al (2006) investigated the effects of estrogen on thyroid 
hormone levels in normal and ovariectomized rats.  Low and high doses of estradiol were 
administered to control and ovariectomized adult female rats, as well as pre-pubertal 
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females.  The researchers found that estradiol increased the thyroid weights of the control 
and pre-pubertal females.  Also, when estrogen replacement was administered to 
ovariectomized rats, the decreased serum T3 levels were normalized.  It was determined 
that neither the low or high dose of estrogen affected circulating TSH concentrations, 
suggesting that the increased thyroid weight and improved T3 levels were direct effects 
of estrogen on the thyroid gland. 
 Studies in cattle have investigated the effects of Synovex-S® implants on 
circulating plasma concentrations of T3 and T4, as well as on growth performance.  An 
experiment by Kahl et al. (1992) used 24 Angus-Hereford crossbred steers in a 56-d 
feeding experiment.  Steers received 4 treatments of control, Synovex-S® ear implant, T3 
injection every other day, or Synovex-S® plus T3 injection every other day.  Jugular 
blood was sampled on d 0 and at 2-week intervals. The steers receiving T3 injections had 
increased T3 concentrations, decreased TSH concentrations and essentially suppressed T4 
production.  However, Synovex-S® implant decreased T3 plasma concentrations, but had 
no effect on TSH or T4 concentrations.  When steers received T3 plus Synovex-S®, this 
treatment had no effect on T3 concentrations; however, this treatment decreased TSH and 
T4 concentrations.  The authors state that this data indicates that the only thyroid 
hormone required to maintain normal or Synovex-S® stimulated body weight gain and 
protein deposition was T3.  Synovex-S® stimulated body weight gain by 22 and 20% and 
protein gain by 35 and 36% in non-T3 and T3-injected steers, respectively. 
 These experiments show that Synovex® growth implants improve growth and 
feed efficiency via changes in GH and thyroid hormones, which ultimately increases lean 
tissue gain. 
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Insulin resistance syndrome and the relationship with adipose tissue and fat 
deposition in non-ruminants 
 
Insulin resistance 
 
 Insulin resistance is a physiological condition in which normal levels of insulin 
are not adequate to elicit an insulin response from tissues such as adipose, skeletal or 
liver (Cosford 1999).  The lack of response to insulin may be caused by disturbances to 
the binding of insulin to receptors on the membrane or disruptions of the insulin signaling 
cascade (Cosford 1999).  In an individual with normal metabolism, insulin is released 
from the pancreatic β-cells in response to a meal and signals glucose uptake by insulin-
sensitive tissues, thus decreasing blood glucose and insulin released by the pancreas 
(Kahn and Flier, 2000; Matthaei et al., 2000).  When an individual is insulin resistant, 
body tissues are no longer sensitive to insulin and glucose is not removed from the blood.  
Because glucose is not removed from the bloodstream, the pancreas responds by 
releasing more insulin, resulting in hyperinsulinemia (Matthaei et al., 2000).  Normal 
blood glucose levels in humans range between 4.5 and 5.0 mmol/L and as an individual 
becomes insulin resistant, these levels increase to between 5.0 and 6.5 mmol/L (Weir and 
Bonner-Weir, 2004).  As blood glucose levels rise and an increasing amount of insulin is 
released, β cells in the pancreas begin to fail and release less insulin (Weir and Bonner-
Weir, 2004).  This abnormal relationship of insulin-resistant tissues and dysfunctional β-
cells in the pancreas usually represents the final stage in the development of Type II 
diabetes (Matthaei et al., 2000).  However, while it appears that the development of 
insulin resistance precedes Type II diabetes, the etiology of insulin resistance is not clear.  
Frequently, insulin resistance is observed in conjunction with hyperinsulinemia, obesity 
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and arterial hypertension (Matthaei et al., 2000).  This collection of disorders may be 
present for many years before Type II diabetes develops. 
Insulin resistance, obesity and Type II diabetes 
The relationship between insulin resistance, Type II diabetes and obesity may be 
considered causative, as it has been suggested that insulin resistance leads to obesity, 
which eventually leads to the development of Type II diabetes (Cosford 1999).  Although 
obesity is strongly correlated with insulin resistance, not all obese individuals have 
insulin resistance, nor does insulin resistance always result in obesity (Cosford 1999).  
Insulin resistance can result in obesity primarily through the anabolic effects of insulin on 
fat metabolism.  Insulin promotes glucose entry into adipocytes, increases production of 
acetyl-CoA, enhances fatty acid entry into adipocytes for adipogenesis and aids in the 
differentiation of preadipocytes to adipocytes (Cosford 1999; Kahn and Flier, 2000).  
Insulin also inhibits lipoprotein lipase, thus decreasing the catabolism of fat (Cosford 
1999).  While an individual may be resistant to insulin and glucose transport is impaired, 
it is possible that adipose tissue remains somewhat sensitive to insulin’s antilipolytic 
effect as lower concentrations of insulin are sufficient to inhibit lipolysis (Kahn and Flier, 
2000).  These promoting factors, along with a lack of exercise, can increase the efficiency 
of weight gain and ultimately lead to obesity. 
Although a characteristic of both obesity and Type II diabetes is insulin 
resistance, it has not been shown that all of insulin’s actions are impaired in individuals 
with both conditions.  Typically, assessing insulin resistance involves measures of 
peripheral glucose disposal and the suppression of hepatic glucose production, both of 
which are impaired.  While glucose homeostasis may be compromised, hepatic 
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lipogenesis and adipose tissue storage in certain depots are usually driven to excess 
(Kahn and Flier, 2000; Frayn 2001).  It is unclear why such discord exists in the action of 
insulin; however, it is likely that changes in insulin signaling pathways and transcription 
factors contribute.   
However, in ruminants some research suggests that insulin resistance may also be 
due to a low capacity of glucose transport (Sasaki 1990).  Lipogenesis from [U-14C] 
glucose was measured in ovine and rat adipocytes with a similar sensitivity to insulin.  A 
glucose concentration of 0.1 mM was used and glucose transport was reduced in the 
ovine adipocytes to 15% of the transport in rat adipocytes in the basal state and all insulin 
concentrations.  If a lower glucose transport capacity is combined with possible changes 
in insulin signaling, the possibility of severe insulin resistance may exist in ruminants fed 
high-carbohydrate diets. 
Insulin resistance and glucocorticoids 
 Glucocorticoids play an important role in the regulation of metabolic homeostasis.  
Specifically, they are released in response to a stressor and assist in allocating energy 
stores both after the stress has ended and during periods of prolonged stress.  Indeed, 
their natural role is to enhance gluconeogenesis in the liver and inhibit insulin-dependent 
glucose uptake in the periphery.  Overall, glucocorticoids oppose the actions of insulin 
and excess glucocorticoids, especially long-term presence, creates a state of hypertension, 
central obesity and glucose intolerance (Andrews and Walker, 1999).  In the long-term, 
glucocorticoids are capable of inducing insulin resistance, and many researchers use 
compounds such as DEX to induce insulin resistance and study this syndrome. 
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Mechanisms of glucocorticoid-induced insulin resistance 
One way in which glucocorticoids can induce insulin resistance is through the 
decreased translocation of glucose transporters (GLUT 4) to the surface of muscle and 
adipose cells.  Dimitriadis et al. (1997) used male Wistar rats injected with 0.5 mg/d DEX 
for 5 d to induce insulin resistance.  Soleus muscle was removed and examined for rates 
of glucose transport using 3-O-methylglucose and GLUT4 abundance.  3-O-
methylglucose is a glucose analogue which is transported like glucose but not further 
metabolized, and therefore provides a direct estimate of the rate of glucose transport 
(Narahara and Ozand, 1963).  Dexamethasone decreased the rate of 3-O-methylglucose 
transport into the soleus muscle at physiological concentrations of insulin.  These results 
suggest that glucose transport was decreased through an effect of DEX on the sensitivity 
of the muscle to insulin.  Furthermore, the abundance of GLUT transporters in the 
membrane of the muscle cells was assessed when stimulated by insulin.  Dexamethasone 
reduced insulin-stimulated increases in GLUT4 translocation in the soleus muscle by 
approximately 60%.  This suggests that the effect of DEX on insulin-stimulated glucose 
transport is via a decrease in the translocation of the GLUT4 glucose transporters from 
cytosol to the plasma membrane (Dimitriadis et al., 1997). 
Glucocorticoids also promote insulin resistance through the inhibition of glucose-
stimulated insulin secretion from pancreatic β-cells.  As insulin sensitivity in muscle and 
adipose tissue decreases and blood glucose concentrations remain elevated, the pancreas 
compensates by releasing more insulin from the β cells.  However, the presence of 
glucocorticoids inhibits the release of insulin from the pancreatic β cells, thus 
precipitating insulin resistance.  Glucocorticoids mediate their effects on decreased 
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insulin secretion from the pancreas through a glucocorticoid receptor located in 
pancreatic β-cells (Fisher et al., 1990).  This receptor is a nuclear hormone receptor that is 
a ligand activatable transcription factor (Beato et al., 1995).  Delaunay et al. (1997) 
evaluated the role of glucocorticoids in β-cell function by increasing the glucocorticoid 
sensitivity of β-cells in transgenic mice.  This increase in sensitivity was accomplished by 
overexpressing the glucocorticoid receptor under the control of the insulin promoter.  
Glucose homeostasis and β-cell function were evaluated in mice that were 3-4 months 
old.  These mice were fasted overnight and then dosed with 0.5 or 2 g glucose/kg BW.  
Transgenic and non-transgenic mice had identical fasting blood glucose concentrations 
and similar blood glucose levels 5 or 10 minutes after intravenous injection.  However, at 
60 minutes following intravenous injection of either 0.5 or 2 g glucose/kg BW, transgenic 
mice exhibited higher blood glucose concentrations compared to control mice.  
Furthermore, the transgenic mice had lower fasting plasma insulin concentrations, and 
reduced plasma insulin at 5 and 60 minutes following glucose injections compared to the 
control mice.  These data indicate defective insulin release from the β-cells of the 
pancreas in mice with increased sensitivity to glucocorticoids and shows that 
glucocorticoids directly inhibit insulin release (Delaunay et al., 1997). 
Another way in which glucocorticoids promote insulin resistance is through an 
increase in lipolysis.  Elevated free fatty acids (FFA) are common in Type 2 diabetes, 
insulin resistance and obesity, and are most likely due to increased FFA release 
associated with an expansion of fat mass (Jensen et al., 1989).  Free fatty acids have been 
proposed as providing one of the links between obesity and insulin resistance (Boden and 
Shulman, 2002).  Furthermore, FFA assist in the development of insulin resistance by 
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inhibiting glucose transport through both direct and indirect effects on the GLUT-4 
glucose transporter.  A direct effect may occur through GLUT-4 synthesis or vesicle 
trafficking, budding or fusion (Kahn 1995).  Indirect effects likely occur through the 
modification of upstream insulin signaling events (Dresner et al., 1999). 
Glucocorticoids have been proposed to play a role in increasing lipolysis from 
adipose tissue, thus leading to increased plasma FFA concentrations (Divertie et al., 
1991; Samra et al., 1998).  Furthermore, Samra et al. (1998) observed that while there 
was an increase in the systemic appearance for glycerol during hypercortisolemia, there 
was a decrease in FFA efflux from abdominal tissue.  Based on these findings, a study by 
Djurhuus et al. (2002) examined the effect of an acute physiological elevation of 
circulating cortisol concentrations on systemic and regional adipose tissue.  These 
researchers sought to determine whether cortisol preferentially stimulates lower body 
adipose tissue lipolysis as opposed to abdominal lipolysis.  Seven healthy young adult 
males (age 27 ± 2.5) were used in a single-blind, placebo-controlled, randomized trial.  
After an overnight fast, the subjects were injected with either hydrocortisone sodium 
succinate or 0.09% saline and blood samples collected for approximately five hours for 
the analysis of serum cortisol and FFA.  The release of glycerol from both the abdominal 
and femoral interstitial areas was also determined.  The researchers found that cortisol 
increased serum FFA and glycerol, while there was no difference in the release of 
glycerol from the upper (abdominal) or lower (femoral) body regions.  These results 
suggest that cortisol increases systemic lipolysis, which may promote insulin resistance.  
However, this study proposes no difference in the lipolysis between the abdominal region 
and other regions of the body (Djurhuus et al., 2002). 
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Insulin resistance and adipose depots 
 It has been suggested that a relationship exists between specific fat depots and 
insulin resistance.  Specifically, there appears to be a correlation between fat in the 
visceral and subcutaneous abdominal regions and insulin resistance (Bonora 2000).  
Research has shown that visceral fat cells are more sensitive to the lipolytic effect of 
catecholamines and less sensitive to the antilipolytic effect of insulin; therefore, more 
FFA are released from this fat depot and contribute to insulin resistance by decreasing 
glucose transport (Kahn and Flier, 2000).  The net result of this increase in lipolysis from 
the visceral fat depot is diversion of FFA towards nonadipose tissues such as the liver and 
muscle.  The blood supply of the visceral fat depot drains directly into the portal vein, 
which travels directly to the liver.  The liver must then repackage the FFA into 
triglycerides and very low density lipoproteins (Lewis et al., 2002).  Similarly, a release 
of FFA from other adipose tissues delivers these FFA to the periphery.  As adipose tissue 
becomes insulin resistant through down-regulation of GLUT4, FFA and other fuels may 
be diverted from adipose to nonadipose tissues, such as muscle (Lewis et al., 2002).  As 
FFA and possibly glucose are taken up by muscle tissue, they are converted to 
intramuscular fat.  However, it is not known whether triglycerides accumulate in the 
muscle of insulin-resistant individuals because of a defect in fatty acid oxidation, 
increased FFA flux to muscle or because of an imbalance between FFA uptake, 
esterification or triglyceride lipolysis (Lewis et al., 2002). 
 As insulin resistance progresses, muscle usually becomes insulin-resistant; this is 
significant, as skeletal muscle accounts for 70-80% of whole-body insulin-stimulated 
glucose uptake (DeFronzo et al., 1981).  It is likely that skeletal muscle becomes insulin 
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resistant as a result of increased availability of circulating FFA.  Randle et al. (1963) 
suggested that an increase in FFA supply to the muscle leads to preferential fat oxidation, 
therefore leading to a reduction in uptake and oxidation of glucose.  However, while the 
reduction in glucose oxidation has been confirmed (Boden et al., 1991), the contribution 
of this cycle to the reduction in insulin-stimulated glucose uptake remains unclear 
(Hegarty et al., 2003).  While lipid infusion causes inhibition of glucose oxidation, 
insulin stimulation of glucose uptake is unaffected for several hours and its impairment is 
more closely associated with a reduction in glycogen synthesis rather than glucose 
oxidation (Hegarty et al., 2003). 
 
Insulin resistance and tumor necrosis factor-α 
 While the mechanisms involved in the causation of insulin resistance are complex 
and remain to be fully elucidated, the involvement of tumor necrosis factor-α (TNF-α) in 
adiposity and the development of insulin resistance has been determined (Hotamisligil et 
al., 1995).  TNF-α is a cytokine produced by macrophages and involved in systemic 
inflammation (Beutler and Cerami, 1989).  It has also been shown to be highly expressed 
in the adipose tissue of obese subjects (Hotamisligil et al., 1995) and a lack of TNF-α 
seems to protect obese mice against insulin resistance (Uysal et al., 1997).  The 
mechanistic effects of TNF-α seem to be through paracrine and autocrine action of 
adipocytes in white adipose tissue (Arner, 2003).  A study by Hotamisligil et al. (1996) 
demonstrated that exposure of human adipocytes to TNF-α inhibits insulin signaling and 
induces insulin resistance by affecting certain insulin receptor substrate proteins. 
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 In addition to the effects of TNF-α on adipocytes, a direct effect on skeletal 
muscle has been difficult to establish.  As skeletal muscle is responsible for 
approximately 80% of glucose disposal, insulin resistance is first detectable in this organ 
(Lorenzo et al., 2008).  In subjects with Type II diabetes, the number of GLUT4 proteins 
available to transport glucose inside the cell can remain normal; however, the capacity of 
insulin to stimulate the translocation of GLUT4 to the plasma membrane may be 
impaired (Lorenzo et al., 2008).  This impairment of insulin may be due to the effects of 
TNF-α, but studies have shown conflicting results.  A study by Nolte et al. (1998) 
showed no inhibitory effect of TNF-α on insulin-induced glucose uptake, while another 
study by Rosenzweig et al. (2002) showed an inhibitory effect of TNF-α on insulin 
action.  However, further research seems to support the idea of an impairment of insulin 
by TNF-α.  A study by de Alvaro et al. (2004) used differentiated cultures of neonatal rat 
skeletal muscle maintained in a low-glucose medium.  These cells responded to acute 
insulin stimulation by increasing glucose uptake and GLUT4 translocation to the plasma 
membrane.  However, when TNF-α was added to the medium, insulin-stimulated glucose 
uptake and GLUT4 translocation were impaired.  The results of these studies show the 
important role of the cytokine TNF-α in the development of insulin resistance in both 
adipose and skeletal muscle tissue of non-ruminants. 
 In ruminants, the relationship between TNF-α and insulin has been studied in 
dairy cows and steers (Kushibiki et al., 2001; Ohtsuka et al., 2001).  Kushibiki et al. 
(2001) used Holstein steers between 16 and 18 months of age and treated them with 
either a subcutaneous injection of saline or rbTNF once daily for 9 d.  Plasma glucose, 
NEFA and insulin concentrations were measured and increased in the steers treated with 
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rbTNF compared to the control group.  Another study by Ohtsuka et al. (2001) evaluated 
Holstein dairy cows diagnosed with fatty liver.  Cows were classified into 3 groups based 
on the severity of fatty liver and assessed for serum TNF activity and glucose disposal 
rate.  The two groups of cows most severely affected with fatty liver were determined to 
have higher serum TNF concentrations compared to the group with mild fatty liver.  
Also, the severely affected groups had lower glucose disposal rates compared to the 
mildly affected group.  The results of this study showed that in dairy cows diagnosed 
with fatty liver, there is a correlation between increased serum TNF concentrations and 
insulin resistance, as shown by decreased glucose disposal rates.  Overall, these studies 
demonstrate that as in non-ruminants, there is a relationship between increased TNF-α 
and insulin resistance. 
 The relationship between insulin resistance, obesity and Type II diabetes is very 
complex and much remains to be determined regarding how the disorders develop and 
are associated.  Furthermore, most of the research related to these areas has been 
performed in non-ruminants, mainly humans and rats.  Further research needs to be 
conducted in ruminants in order to understand the extent and mechanisms controlling 
how high-carbohydrate diets might induce insulin resistance through obesity. 
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Chapter 3 
Experiment 1 
Effects of chlortetracycline (CTC) and Synovex-S® on growth rate and on plasma 
growth hormone (GH) and thyroid hormone concentrations following 
administration of thyrotropin-releasing hormone (TRH) and GH-releasing hormone 
(GHRH) in beef steers 
 
Introduction 
Subtherapeutic feeding of chlortetracycline (CTC) has been reported to have 
growth-promoting effects for ruminants, swine, and poultry, but the mechanisms 
responsible for these effects are unknown.  It is generally hypothesized that growth 
promotion by antibiotics in ruminants is a result of effects on digestive tract 
microorganisms or gut wall thinning.  However, CTC-induced changes in carcass 
composition in calves suggest that this antibiotic may also influence growth via an 
endocrine mechanism (Landagora et al., 1957).  Recently we have shown oral 
administration of CTC to temporally elevate circulating IGF-1 (McLeod et al., 2003) 
concentrations; however, chronic administration of CTC reduced plasma concentrations 
of growth hormone (GH), thyroid-stimulating hormone (TSH), and thyroxine (T4) 
following injection of thyrotropin-releasing hormone (TRH) and growth hormone-
releasing hormone (GHRH) in beef steers (Rumsey et al., 1999d).  Corresponding with 
this shift in circulating hormone concentrations were both an increase in subcutaneous fat 
and a marbling score (Rumsey et al., 2000).  Taken in concert, these data support the 
notion that CTC affects tissue deposition by suppressing pituitary responsiveness to 
GHRH and TRH. 
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 Implants containing estradiol and progesterone are used in finishing beef cattle to 
improve feed efficiency and enhance lean tissue growth.  Contrary to the reduced plasma 
concentrations of GH, TSH, and T4 observed with CTC administration, implant-
stimulated increases in cattle protein accretion are considered to be mediated by increases 
in GH, IGF-1, TSH, and thyroid hormones (Gopinath and Kitts, 1984b; Johnson et al., 
1996; Rumsey et al., 1997).  Although it is clear that estrogenic implants repartition 
nutrients from fat to muscle tissue, the manner in which hormone profiles are altered 
during repartitioning is still unclear (Lemieux et al., 1990).  Moreover, with the exception 
of circulating IGF-1 concentrations (Johnson et al., 1996), little research has investigated 
the time-course effects of hormonal implants on GH, TSH, and thyroid hormones.  
 Considering the opposing actions of CTC and growth implants on pituitary and 
thyroid hormone profiles and the lack of information regarding the time-course effects of 
both CTC and growth implant, the primary objective of the current study was to test the 
effects of oral CTC and Synovex-S® on circulating concentrations of GH and thyroid 
hormones induced by an injection of TRH + GHRH in finishing beef steers on d 30, 56, 
and 106 of a 112-d finishing study.  Additionally, we measured the effects of CTC and 
Synovex-S® on growth performance and carcass traits of these steers to evaluate the 
relationship between hormone release and tissue deposition. 
 
Materials and Methods 
Animals and Treatments   
 The protocol for the research discussed in this report was approved by the 
University of Kentucky Institutional Animal Care and Use Committee.  Twenty-four 
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Simmental-Angus crossbred steers were purchased from a single farm in Central 
Kentucky.  Steers were initially housed on pasture for 30 d upon arrival at the University 
of Kentucky Animal Research Center, during which time they were dewormed using 
ivermectin (Merial, Duluth, GA) and vaccinated using Bovi-Shield™4 and Ultrabac®7 
(Pfizer Animal Health, Exton, PA).  After 30 d, steers were moved to group pens (4 
steers/pen) for a 30-d backgrounding period during which they were adapted to corn 
silage until a body weight (BW) of approximately 340 kg was achieved.  The group pens 
measured 14.6 x 2.4 m and were located on a concrete pad partially covered with a roof.  
The steers had continuous access to automatic waterers. 
 After the 30-d backgrounding period, steers were limit-fed two transition diets for 
an additional 30 d at 2.25% BW for adaptation to ad libitum intake of the experimental 
diet (Table 3.1).  During this time, adaptation to handling and haltering was accomplished 
by tying groups of four steers in a group-pen twice weekly.  Steers were separated into 
three groups of eight steers to facilitate intensive blood sampling on hormone challenge 
days.  The experiment start day for group 2 was one week after group 1, while group 3 
started three weeks after group 1.   
Ten days before each group started on the experiment, steers were moved into 
individual pens measuring 2.4 x 1.8 m and covered by a roof.  Each pen had an individual 
feed bunk and waterer.  During this period, steers were initially limit-fed the 
experimental diet at 2.0% BW, followed by a gradual step-up to ad libitum intake over a 
9-d period.  For the duration of the experiment, steers were exercised by turning them out 
into larger pens in groups of four from 0730-0900 each day.  Before feeding, individual 
body weights were determined once every two weeks for each group of steers; however, 
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initial and final body weights were determined by weighing steers on two consecutive 
days. 
Across groups, steers were assigned randomly to a 2 x 2 factorial arrangement of 
treatments.  Treatments included a corn meal + molasses carrier containing either 0 or 
350 mg CTC (Aureomycin, Alpharma Animal Health, Fort Lee, NJ) and Synovex-S® ear 
implant (200 mg progesterone + 20 mg 17-β estradiol benzoate) or no Synovex-S®.  The 
level of CTC used in this study was the same as that used by Rumsey et al. (1999d, 
2000), which had been shown to induce changes in carcass traits and pituitary and thyroid 
responsiveness.  Steers were implanted or not implanted with Synovex-S® on d 0; after 
which steers initially implanted were re-implanted on d 56.  The experimental diet was 
formulated using two protein supplements:  Protein supplement 1 was formulated to 
provide 105% of the metabolizable protein requirement for large-frame steers (350 kg 
BW) gaining 1.60 kg/d and was fed until d 56 of the experiment; Protein supplement 2 
was formulated to provide 105% of the metabolizable protein requirement for large-
frame steers (450 kg BW) gaining 1.60 kg/d and was fed from d 57-112 (NRC, 1996).  
The carrier or carrier plus CTC (500 g) was supplied daily at 0900.  Steers were returned 
to the individual pens from the exercise lot and allowed one hour to consume the 
treatments before feeding at 1000.  Orts were measured daily immediately after steers 
were turned out for exercise. Throughout the study, amount of feed offered was adjusted 
to maintain approximately 20% orts. 
Releasing-hormone challenges were conducted on d 30, 56, and 106.  Jugular 
catheters were placed in steers 12 to 18 h prior to hormone challenge and feed was 
removed at 1700 on days prior to hormone challenge.  On the day of hormone challenge, 
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steers were injected via jugular catheter at 0800 with a 10-mL physiological saline bolus 
containing TRH (1.0 µg/kg BW) and GHRH (0.1 µg/kg BW).  Relative to hormone 
challenge, serial, jugular blood samples (10 mL) were collected at -30, -10, 0, 5, 10, 15, 
20, 30, 45, 60, 120, 240, and 360 min.  Blood samples were centrifuged (1,800 x g @ 4˚C 
for 30 min), plasma removed and frozen (-80˚C), and plasma concentrations of GH, TSH, 
T4, and triiodothyronine (T3) determined by RIA.  Upon completion of the hormone 
challenge, steers were fed their respective supplements (with or without CTC) and 50% 
of their daily allotment of feed. 
After 112 d on experimental treatments, steers were slaughtered in groups of four 
steers per day over a one-week period in the University of Kentucky abattoir.  Each group 
contained one steer from each treatment, and selection was from heaviest to lightest 
within each treatment.  A merit evaluation of each carcass was done according to USDA 
standards and performed by a qualified meat scientist.  The carcass merit indicators were 
hot carcass weight (HCW), dressing percentage, longissimus muscle area, fat over 
longissimus muscle, kidney, pelvic, heart fat (KPH), marbling, and bone maturity. 
Sample Analyses   
 Concentrations of GH and TSH were determined by previously validated RIA 
(Elsasser et al., 1989, 1992, respectively).  The intraassay CV were 7.0% and 8.3%, 
whereas the interassay CV were 8.5% and 9.0% for the GH and TSH assays, respectively.  
Based on a previous study by Rumsey et al. (1999d) in which full response curves were 
obtained, the timepoints chosen for GH and TSH analyses were -10, 0, 10, 15, 30, 60, and 
120 min for GH, and 0, 20, 30, 45, 60, 120, 240, and 360 min for TSH.  All timepoints 
were used for analyses of T3 and T4.  Thyroxine and T3 concentrations were determined 
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with a RIA (Coat-A-Count® Total T4 and Total T3, respectively, DPC®, Los Angeles, 
CA) with inter- and intra-assay CVs of 7.1 and 5.6% for T4 and 2.8 and 2.4% for T3, 
respectively.  Each assay was validated for the upper and lower limits of the 
physiological response range for bovine plasma.  The recoveries for the upper and lower 
limits averaged 107.5% ± 4.4 and 98.3% ± 0.49 for T4 and T3, respectively.  The lowest 
detectable concentrations across all T4 and T3 assays averaged 0.84 and 0.03 ng/mL, 
respectively.  The GH, TSH, T4, and T3 response curves were evaluated for area-under- 
the-curve (AUC) using GraphPad Prism software (GraphPad Software, Inc., Aurora, 
CO), peak response (visual evaluation of plasma concentrations), and time from 
challenge to peak. 
Statistical Analyses   
 Growth performance and carcass data were statistically analyzed by analysis of 
variance for a 2 x 2 factorial arrangement of treatments and randomized complete block 
design using GLM procedures of SAS (SAS Inst., Inc., Cary, NC, 2003).  The model 
included group, CTC, implant, and CTC x implant interaction.  Hormone data were 
analyzed as a repeated, repeated-measure using MIXED procedures of SAS (SAS Inst., 
Inc., Cary, NC, 2003).  Main plot effects included CTC, implant, and their interaction, 
while the first subplot included day and the interactions, and the second subplot included 
time and the interactions.  The random statement included group, steer(CTC implant) and 
day*steer(CTC implant). The repeated statement included steer(day CTC implant) as the 
subject with a compound symmetry covariant structure.   
 Because of the pulsatile nature of GH release patterns, -10 and 0 timepoint 
samples were simply averaged to generate a baseline value for the GH response curve 
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(Figure 3.1); the zero timepoint sample was used as the baseline value for the TSH 
response curve (Figure 3.2).  Data used to generate T3 and T4 response curves (Figures 
3.3 & 3.4) were adjusted so that hormone concentrations across time reflected a common 
zero-time mean.  In order to adjust T3 and T4 data to a common baseline value, means for 
-30, -10, and 0 timepoint samples were tested for significance using GLM and the 
variance associated with those means was tested for significance using a Levene’s test.  
Means for -30, -10, and 0 timepoint samples for T3 and T4 were not different (P = 0.99 
and P = 0.85, respectively).  Additionally, variances of the individual steer means for T3 
and T4 across d 30, 56, and 106 were not different (P = 1.00), therefore, data for both 
variables were adjusted to a common baseline value.  Main effect means were separated 
using the LS MEANS statements in SAS.  Due to health reasons unrelated to the 
experiment, data from one steer was excluded from analysis; therefore, the control 
treatment contained five animals and the SEM for this group was used for data in all 
tables and figures.  When interactions were significant (P ≤ 0.05), least squares means 
were tested using least significant differences for growth performance and carcass merit 
data, while the slice option in the LS MEANS statement was used before pair-wise 
comparisons were made for all hormone challenge data.  Treatment main effects and 
interactions were considered significant at P ≤ 0.05 and a tendency to be significant at P 
≤ 0.10. 
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Results 
Growth Performance   
Rate of BW gain (calculated as the slope of the line describing change in BW 
over time), dry matter intake (DMI), and efficiency of gain (BW gain per unit of DMI) 
are summarized in Table 3.2.  Regardless of period, there were no treatment effects (P ≥ 
0.14) on DMI throughout the experiment.  During Period 1 (d 0-26), Synovex-S® 
increased BW gain (P = 0.01) by 20% and feed efficiency (P = 0.007) by 23%.  There 
were no treatment effects (P ≥ 0.12) on growth performance during Period 2 (d 27-54).  
However, during Period 3 (d 55-82), Synovex-S® increased BW gain (P = 0.02) by 32% 
and feed efficiency (P = 0.04) by 34%.  During Period 4 (d 83-110), BW gain and 
efficiency of gain were similar (P ≥ 0.40) for all treatments.  Over the entire experiment 
(d 0-110), Synovex-S® increased rate of BW gain (P = 0.009) by 20%, efficiency of gain 
(P = 0.001) by 21%, and final BW (P = 0.007) by 6%.  It is important to reiterate that the 
periods of response to Synovex-S® were observed within the 28-d periods following 
implantation (d 0 and 56) and that CTC demonstrated no effects on growth performance 
throughout the experiment. 
Carcass Merit   
Carcass merit data are summarized in Table 3.3.  Chlortetracycline and Synovex-
S® interacted (P ≤ 0.05) to affect slaughter weight and HCW.  In the absence of CTC, 
steers receiving implant had heavier slaughter weights and HCW (P ≤ 0.002) compared to 
steers receiving no implant.  However, in the presence of CTC, implant had no effect (P ≥ 
0.38) on slaughter weight or HCW.  Similarly, in the absence of CTC, longissimus dorsi 
area was greater (P = 0.008) in steers receiving implant compared with those receiving no 
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implant.  Conversely, implant had no effect (P = 0.96) on longissimus dorsi area in the 
presence of CTC (interaction, P = 0.05).  Concurrently, longissimus fat cover and yield 
grade were lower (P = 0.03) in implanted steers in the absence of CTC, but implant had 
no effect (P ≥ 0.38) when steers were fed CTC (interaction, P ≤ 0.05).  There was no 
effect (P ≥ 0.19) of treatment on KPH or marbling score.  Bone maturity was lower (P = 
0.01) for implanted steers. 
Growth Hormone   
The effects of estrogenic implant and CTC on changes in plasma GH 
concentrations following injection of TRH + GHRH are shown in Figure 3.1.  The effect 
of time was significant (P < 0.0001).  The concentration of plasma GH increased 
following challenge injection, reached peak concentrations approximately 10 min post-
injection, and returned to baseline concentrations by 120 min.  There was a tendency (P = 
0.10) for higher plasma GH concentrations in implanted steers compared to non-
implanted steers following challenge (Figure 3.1); however, there was no effect (P = 
0.80) of CTC on plasma GH concentrations. 
 A summary of the effects of CTC and Synovex-S® on characteristics of the GH 
response curve is shown in Table 3.4.  Baseline concentrations of GH (the average of 
samples obtained at -10 and 0 min relative to injection time) were not different (P ≥ 0.13) 
between treatments.  Time to peak was shorter (P = 0.05) for steers receiving implant 
compared to steers receiving no implant.  However, implant did not alter (P ≥ 0.14) the 
magnitude of the GH response or area under the response curve.  Overall, oral 
administration of CTC had no effect (P ≥ 0.12) on GH response curve characteristics and 
there were no CTC x implant interactions (P ≥ 0.39). 
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Thyroid-Stimulating Hormone   
The effects of Synovex-S® on changes in plasma TSH concentrations after TRH 
+ GHRH injection are shown in Figure 3.2.  The effect of time was significant (P < 
0.0001).  Concentration of plasma TSH increased following hormone challenge, reached 
peak concentrations approximately 120 min post-injection, and returned to near baseline 
6 h after challenge.  The implant by time interaction after challenge was significant (P = 
0.03), with greater (P ≤ 0.05) TSH concentrations at 45, 60, and 120 min, and a tendency 
for greater (P = 0.09) TSH concentrations at 240 min, for implanted compared to non-
implanted steers.  Conversely, at all other time-points along the TSH response curve, 
there were no differences in the TSH response between implanted and non-implanted 
steers.  Similarly, there was no effect (P = 0.95) of CTC on the TSH response over the 
360-min challenge period (data not shown). 
 Characteristics of the TSH response curve are shown in Table 3.4.  Baseline 
concentrations of plasma TSH were greater (P = 0.03) for implanted compared to non-
implanted steers; in contrast, baseline concentrations of TSH were unaffected (P = 0.58) 
by CTC.  There were no effects (P ≥ 0.19) of treatment on time to peak or magnitude of 
the TSH response.  Although there were no treatment effects on change in TSH 
concentrations, overall peak concentrations showed a slight tendency to be greater (P = 
0.11) for implanted compared to non-implanted steers.  There were no effects (P ≥ 0.20) 
of treatment on TSH area under the response curve. 
Thyroid Hormones   
The effects of Synovex-S® and CTC on changes in plasma T3 concentrations 
over time relative to injection of TRH + GHRH are shown in Figure 3.3.  Because there 
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was a significant CTC x implant x time interaction (P = 0.004), the means for implanted 
and non-implanted steers are presented in the absence and presence of CTC.  In the 
absence of CTC, implanted steers had greater (P ≤ 0.02) T3 responses 120, 240, and 360 
min following the releasing hormone challenge relative to the non-implanted steers.  
However, in the presence of CTC, implanted steers had only a tendency (P = 0.06) for a 
greater response at 240 min compared to non-implanted steers. 
 There were no effects (P ≥ 0.41) of treatment on the baseline concentrations of T3 
(Table 3.4); however, area under the response curve tended to be greater (P = 0.07) for 
implanted compared to non-implanted steers.  Additionally, there was a CTC x implant 
interaction (P = 0.02) for time to peak for T3.  In the absence of implant, time to peak 
increased (P = 0.03) for steers receiving CTC compared to those not receiving CTC.  
Although the magnitude of T3 response was greater (P = 0.01) for implanted steers 
compared to steers receiving no implant, there tended (P = 0.09) to be an interaction 
between CTC and implant.  In the absence of CTC, the magnitude of the T3 response was 
greater (P = 0.005) for implanted compared to non-implanted steers.  Conversely, in the 
presence of CTC, the magnitude of the T3 response was not affected (P = 0.46) by 
implant.   
 The effects of Synovex-S® and CTC on changes in plasma T4 concentrations 
following the injection of TRH + GHRH are shown in Figure 3.4.  The response of T4 
plasma concentrations to TRH + GHRH challenge injection in all steers continued to 
increase throughout the sampling period, therefore a complete response curve was not 
obtained.  A review of individual animal data confirmed that the highest concentrations 
of T4 for all steers occurred at 360 min; therefore, peak concentrations must have 
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occurred at 360 min or later.  Thyroxine concentrations increased (P < 0.0001) after 
challenge injection; however, there were no effects (P ≥ 0.34) of treatment on plasma T4 
concentrations.  Additionally, there were no treatment effects (P ≥ 0.41) on baseline 
concentration, magnitude of response, or area under the response curve (Table 3.4).  
Time to maximum response was not analyzed statistically because a complete response 
curve was not obtained; therefore a peak value could not be determined. 
Effects of Day of Challenge on Pituitary and Thyroid Hormone Responses   
Although there were no effects of day of challenge on GH, magnitude of 
response, as well as area under the response curve for TSH, T3 and T4 were influenced 
by day of challenge (data not shown).  Day was also significant (P ≤ 0.05) for the peak 
TSH concentrations, and baseline concentrations and time to peak for T3.  Although the 
effect of day was significant for these variables, there was not a consistent pattern of an 
increased or decreased response throughout the experiment.  Moreover, there were no 
treatment x day interactions for any hormone variable measured, therefore all treatment 
effects were independent of day. 
 
Discussion 
 Previously, we have shown in beef steers that oral administration of CTC 
attenuated pituitary and thyroid hormone responses to a TRH + GHRH challenge on d 56 
and increased overall fat deposition during a 91-d experiment (Rumsey et al., 1999d).  In 
contrast, anabolic implants containing progesterone + estrogen, i.e. Synovex-S®, have 
been shown to increase circulating concentrations of GH and thyroid hormones in 
response to a GH or TRH + GHRH challenge (Gopinath and Kitts, 1984a; Rumsey et al., 
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1997) and to increase lean body tissue accretion (Rumsey et al., 1999b).  However, 
research has not evaluated the response of circulating hormone concentrations of GH and 
thyroid hormones to a growth implant using a releasing-hormone challenge at multiple 
timepoints over the entire course of the feedlot finishing period, nor have the interactive 
effects of CTC and growth implant on circulating hormone concentrations been 
determined.  Furthermore, as CTC has been shown to diminish the pituitary and thyroid 
hormone response to a TRH + GHRH challenge at a single timepoint (d 56) in the study 
by Rumsey et al. (1999d), it was of interest to determine if this response was acute or 
chronic.  Therefore, the primary objective of the current study was to test the effects of 
oral CTC and Synovex-S® on circulating concentrations of GH and thyroid hormones 
induced by an injection of TRH + GHRH in finishing beef steers on d 30, 56, and 106 of 
a 112-d finishing study.  Additionally, we measured the effects of CTC and Synovex-S® 
on growth performance of these steers to determine if changes in circulating hormone 
concentrations were reflective of changes in growth and carcass traits.  However, the 
results of the current experiment showed no effect of CTC alone on the response of 
pituitary or thyroid hormones to the releasing hormone challenge on d 30, 56, or 106; 
there was also no increase in fat deposition with CTC by d 112.  These results disagree 
with the previous reports of Rumsey et al. (1999d, 2000), which demonstrated decreased 
concentrations of circulating GH and thyroid hormones in response to releasing-hormone 
challenge and subsequent increases in fat deposition.  However, the lack of an effect of 
CTC on circulating hormone concentrations in the current experiment is consistent with 
the observed lack of change in fat deposition.  Furthermore, a recent study by Kitts et al. 
(2006) in which 96 steers were used to evaluate the effects of CTC and Revalor-S® on 
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growth and carcass characteristics also showed no effect of CTC on fat deposition of 
finishing beef steers.  Regardless of the discrepancies in the CTC response between these 
studies, this experiment demonstrates the effects of Synovex-S® on growth performance 
and hormonal profiles concurrently over the course of the finishing phase, as well as 
interactions between CTC and Synovex-S®. 
Growth Performance   
 The DMI, BW gain, and feed efficiency data in this experiment are in agreement 
with data concerning use of Synovex-S® implants in growing and finishing cattle 
(Rumsey et al., 1992a, 1996, 1999a,c; Mader et al., 1994).  The greatest improvements in 
BW gain and feed efficiency were observed immediately following the administration of 
Synovex-S® (Periods 1 & 3).  The 32% increase in BW gain observed for implanted 
steers during Period 3 was not unexpected, as steers were reimplanted with Synovex-S® 
on d 56.  However, there was a diminished response in BW gain to Synovex-S® during 
Periods 2 & 4, suggesting a reduction in the effectiveness of this growth implant over a 
56-d period.  Although BW gain reduced by 32% in the presence, and 14% in the absence 
of CTC for implanted compared to non-implanted steers during Period 2, gain reduced by 
only 6% and 12% for these same groups during Period 4.  While it appears that CTC may 
have contributed to the diminished BW gain during Period 2, this was not the case during 
Period 4, again suggesting an overall reduction in the effectiveness of Synovex-S® 
during a 56-d period.  The tremendous response observed during Periods 1 & 3 implies 
that the positive effects of estrogenic implants are most apparent in the periods 
immediately following implantation.  It is important to note that because there was an 
increase in BW gain for implanted steers during Periods 1 & 3 and no change in DMI, 
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there was an increase in feed efficiency during these periods.  As previously stated, there 
are rarely changes in DMI when cattle are treated with anabolic implants, therefore an 
increase in DMI during this experiment was not expected.  Finally, increased BW gain 
and feed efficiency during Periods 1 & 3 resulted in an overall increase in these 
measurements for the entire experiment (20% and 19%, respectively).  These responses 
are similar to previous research showing increases of 18% and 12%, respectively 
(Hermesmeyer et al., 2000).   
 Although BW gain and feed efficiency increased with the addition of estrogenic 
implants, these measurements were not affected by the addition of CTC.  Previously 
Rumsey et al. (2000) reported that oral administration of CTC did not alter BW gain in 
growing steers, but tended to improve efficiency of BW gain.  Similarly, Kitts et al. 
(2006) showed that CTC alone did not affect growth performance of finishing cattle over 
the course of a 139-d feeding period; however, CTC attenuated the positive effects of 
Revalor-S® on efficiency of gain during the latter 54 d of the feeding period.  Overall, 
the effects of CTC on growth performance have been variable.  Research has shown 
increased BW gain and efficiency in growing but not finishing steers, whereas other data 
suggest improvements in weight gain for feedlot steers (Perry et al., 1954; Brown et al., 
1975).  It has been suggested that the effects of CTC on growth performance are more 
apparent under stressful conditions that are immunologically challenging to the animal 
(Visek, 1978).  In the current study and those of Rumsey et al. (2000) and Kitts et al. 
(2006), steers were vaccinated and backgrounded for a minimum of 30 d, and adjusted to 
the experimental diet prior to initiation of the experiment.  In contrast to Kitts et al. 
(2006), while ADG was numerically lower for implanted steers in the presence of CTC 
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(with the exception of Period 1) in the current experiment, CTC did not attenuate effects 
of implant on efficiency of gain.  Although the reason for the differences in growth 
response between the current study and that of Kitts et al. (2006) is unclear, the 
physiological maturity of the steers and type of implant (estrogen vs. trenbolone acetate + 
estrogen) differed in each experiment, which could account for the lack of consistency in 
responses. 
Carcass Merit   
 The primary objective of the current experiment was to evaluate the effects of oral 
CTC and Synovex-S® on the release of GH and thyroid hormones induced by an 
injection of TRH + GHRH in finishing beef steers during a 112-d study.  However, we 
also sought to examine the relationship between time-course of the hormonal responses to 
the treatments and final body composition, as changes in GH and thyroid hormone status 
should be indicative of changes in overall body composition.  Contrary to the previous 
study by Rumsey et al. (2000), the current data indicated no changes in intramuscular or 
subcutaneous fat for cattle fed CTC alone.  Likewise, the study by Kitts et al. (2006) 
showed no change in carcass characteristics for cattle fed CTC alone or in the presence of 
growth implant.   
In general, estrogenic implants have been shown to increase slaughter weight in 
finishing cattle (Mader et al., 1994; Rumsey et al., 1999b; Hermesmeyer et al., 2000).  
While our data generally agree with these observations, interactions between implant and 
CTC occurred for slaughter weight and HCW.  These interactions are explained by 9% 
and 10% increases in both slaughter weight and HCW for steers receiving growth implant 
compared to those receiving no implant in the absence of CTC.  However, the positive 
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effects of Synovex-S® on slaughter weight and HCW were diminished in the presence of 
CTC.  Because there was no difference in the dressing percentage for any treatment 
group, changes in HCW were directly proportional to changes in slaughter weight. 
Although an interaction between steers receiving implant and CTC was largely absent in 
the growth performance data, the attenuation of the effects of Synovex-S® by CTC on 
slaughter weight and HCW is consistent with the previous observed decrease in growth 
efficiency of cattle implanted with Revalor-S® (Kitts et al., 2006).  
 The observed increase in longissimus muscle area and decrease in fat cover for 
implanted compared to non-implanted steers alone is in agreement with previous research 
showing increases in protein gain and a reduction in fat gain (Solis et al., 1989; Lemieux 
et al., 1990).  Additionally, both longissimus fat cover and intramuscular fat have 
previously been shown to increase in CTC-fed steers (Bohman and Wade, 1958; Harvey 
et al., 1968; Rumsey et al., 2000).  Thus, the current observed interaction between CTC 
and growth implant for longissimus muscle area and fat cover is consistent with the 
aforementioned effects of each of these compounds alone.  However, the observation that 
CTC failed to increase fat deposition in the current experiment agrees with the report of 
Kitts et al. (2006), where no effect of CTC, either alone or in combination with growth 
implant, on subcutaneous or intramuscular fat was observed.  Control (-CTC, -implant) 
steers had 13% smaller longissimus muscle area and 43% greater fat cover compared to 
all other treatments.  Given the aforementioned and the fact that three of five steers in the 
control treatment had subcutaneous fat thicknesses in excess of 0.89 cm, it is equivocal 
whether the observed interactions are a function of treatment.  Finally, the absence of an 
overall effect of CTC on body composition as measured by carcass characteristics agrees 
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with the concurrent finding that CTC did not attenuate GH or thyroid hormone status.   In 
the previous experiment by Rumsey et al. (1999d, 2000), changes in body composition 
appear to be associated with changes in GH and thyroid hormones with the 
administration of oral CTC; however, it is unclear whether the lack of change in both 
carcass composition and hormonal status observed in the current experiment supports this 
hypothesis. 
Growth Hormone   
 Previous researchers assessed the pulsatile pattern of GH secretion and 
demonstrated that baseline GH concentrations were higher in steers 20 d after implanting 
with Synovex-S® compared to steers receiving no implant (Gopinath and Kitts, 1984a).  
In the current experiment, we observed only a slight tendency (P = 0.13) for increased 
GH baseline concentrations; however, it is important to note that the blood samples used 
to measure baseline GH concentrations in the current experiment were those collected 10 
and 0 min prior to the TRH + GHRH injection.  Due to the pulsatile nature of GH release 
from the pituitary, blood samples must be collected for at least several hours to obtain an 
accurate profile of baseline concentrations (Davis et al., 1977; McLeod et al., 1995).  
Thus, the samples collected in the current experiment would only provide a crude 
estimate of the baseline GH concentration. 
 The experiment by Gopinath and Kitts (1984a) also demonstrated that Synovex-
S® increases GH secretion from the pituitary rather than clearance from circulation.  This 
is consistent with the data from the current experiment, which showed a decrease (P = 
0.05; Table 3.4) in the time to peak for GH and the overall response curve of GH 
concentrations across time induced by a TRH + GHRH challenge tended (P = 0.10; 
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Figure 3.1, Panel A) to be greater for the implanted compared to the non-implanted 
steers.  Taken together, the latter observation suggests that the pituitaries of implanted 
steers may have been more sensitive to GHRH, leading to a quicker release of the 
available GH pool.  Estrogen receptor-α is highly expressed in the anterior pituitary and 
has been shown to increase the number of GH-secreting cells (Chowen et al., 2004; 
Childs et al., 2005).  Additionally, 70% of GHRH neurons contain estrogen receptor-α, 
and estradiol replacement in aromatase-knockout, female mice have been shown to 
increase levels of GHRH receptor mRNA expression relative to aromatase-knockout 
mice alone (Kamegai et al., 2001; Yan et al., 2004).  Therefore, increased sensitivity of 
the pituitary gland in steers receiving estrogenic implants could be due to either higher 
affinity or greater number of GHRH receptors. 
Thyroid Hormones   
 Over the course of the current experiment, estrogenic implant enhanced TRH-
induced TSH release, as well as increased the magnitude of the T3 response.  The 
increase in baseline TSH concentrations for implanted steers is in agreement with a 
previous study by Rumsey et al. (1997).  In the current experiment, peak TSH 
concentrations after a TRH challenge tended to be higher for implanted compared to non-
implanted steers (Table 3.4).  This most likely was a function of higher baseline 
concentrations and to a greater extent, larger changes in the magnitude of TSH response 
(Table 3.4).  Interestingly, there was no difference between implanted and non-implanted 
steers in the initial response (20 min, Figure 3.2) of TSH following TRH challenge, 
suggesting that the size of the readily-releasable pool was not different.  This finding is 
supported by research in rats, which failed to demonstrate an effect of estrogen on size of 
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releasable pools of TSH in the pituitary (Franklyn et al., 1987).  However, in the current 
experiment, differences in TSH concentrations occurred at 45, 60, and 120 min following 
challenge for implanted vs. non-implanted steers, suggesting that these animals may have 
a greater ability to synthesize TSH after depletion of the releasable pool (Figure 3.2).  
Rumsey et al. (1997, 1999d) have shown that following a TRH challenge, there is an 
initial increase in plasma concentrations of TSH, followed by a small reduction and 
another increase, which could be a latent stimulation of TSH synthesis.  In addition to 
stimulating the releasable pool of TSH from the pituitary, TRH also stimulates the 
formation of TSH mRNA (Ross et al., 1983), which may be responsible for subsequent 
stimulation of TSH synthesis.  Alternatively, the latent release could also be a result of 
the secretory pulses of TSH that occur every 1-3 h, regardless of feedback inhibition by 
T3 (Samuels et al., 1991; Larsen 2003).  However, the latter appears less plausible 
because of 1) the lack of a treatment effect on the readily releasable pool of TSH and 2) 
the expectation that the bolus dose of TRH was sufficient to induce the release of the 
majority of pre-synthesized TSH.  The latter is supported by the fact that higher doses of 
TRH than those used in the current experiment do not cause a further increase in 
circulating TSH (Rumsey et al., 1997).   
 Following 120 min post-challenge, plasma TSH concentrations began to decrease 
at a time when T3 had almost reached peak concentrations (Figures 3.2 & 3.3, 
respectively).  This sequence of events is illustrated by the hormonal response of an 
individual steer receiving Synovex-S® (Figure 3.5).  As expected, the peak in plasma 
TSH concentration occurred prior to the peak in concentration of T3 and before the 
estimated peak of T4.  A steady, peak TSH concentration occurred by 60 min, while the 
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T3 concentration peaked at 120 min.  Because T3, the metabolically active form of 
thyroid hormone, is synthesized from T4 in peripheral tissues, an increase in circulating 
T3 several hours after TRH challenge is not surprising (Larsen 2003).  Our data is 
consistent with this series of events; plasma TSH began to decrease 120 min post-
challenge (Figure 3.2) and plasma T3 was approaching peak concentrations (Figures 3.3 
& 3.5).  The observation that T4 concentrations continued to rise at 360 min while T3 
concentrations plateaued and began to decrease suggests that 5’-deiodinase activity was 
saturated and/or is reflective of the fact that the half-life of T3 is approximately 1/16 of 
that of T4.     
 It is notable that in the absence of implant, time to peak for T3increased for steers 
receiving CTC compared to those not receiving CTC, implying that CTC delayed the 
initial release of T3 from the thyroid, and/or the conversion of T4 to T3.  This effect of 
CTC was not seen in a previous experiment by Rumsey et al. (1999d); however they 
reported that CTC decreased 5’-deiodinase activity in the pituitary, which is the enzyme 
responsible for converting T4 to T3.  Approximately 80% of circulating T3 is derived 
from 5’-deiodinase activity in the pituitary, liver, kidney, and plasma membrane of most 
peripheral tissues (e.g., muscle; Larsen 2003).  However, 5’-deiodinase activity was not 
measured in the current experiment, thus it is unclear if the T3 time to peak increased due 
to decreased activity of this converting enzyme or if direct release of T3 from the thyroid 
was delayed by CTC.   
Although CTC may have decreased activity of 5’-deiodinase, Synovex-S® may 
have increased the conversion rate of T4 to T3 in the peripheral tissues, pituitary, liver, or 
kidney.  The T3 response curve demonstrated a CTC x implant x time interaction after the 
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releasing hormone challenge (Figure 3.3).  In concert with greater TSH concentrations for 
implanted compared to non-implanted steers (Figure 3.2), this interaction occurred due to 
greater T3 concentrations 120, 240, and 360 min following challenge injection for 
implanted compared to non-implanted steers in the absence of CTC; however, these 
differences did not occur in the presence of CTC (Figure 3.3).  Although TSH causes an 
acute stimulation of T4 release into the plasma, it stimulates 5’-monodeiodination of only 
small amounts of T4 to T3, thus it is unlikely that the increase in circulating T3 is due to 
an increase in T3 release from the thyroid.  The absence of treatment effects on 
circulating T4 does not negate the possibility that, in the absence of CTC, implant 
increased T4 release, which subsequently increased conversion of T4 to T3.  
Alternatively, increases in 5’-deiodinase activity could have occurred for implanted 
compared to non-implanted steers in the absence of CTC.  An increase in this enzyme 
would have resulted in increased T3 concentrations, but would not necessarily have 
resulted in decreased T4 concentrations due to the large circulating pool of T4 relative to 
T3 (T4 concentrations 43-fold greater than T3).  Conversely, if steers receiving CTC had 
decreased concentrations or activity of the 5’-deiodinase enzyme, differences in the T3 
response of these steers would not be expected.  This might explain the response curves 
in Figure 3.3, Panel B.  Although this explanation appears plausible, it does not 
completely explain all of the T3 response data, especially considering the fact that the 
magnitude of response for T3 (Table 3.4) tended (P = 0.09) to show a CTC x implant 
interaction.  This interaction reflects a marginal decrease (0.06 ng/mL) in the implant 
response in the presence of CTC and an increase (0.14 ng/mL) in the response of CTC in 
the absence of implant.  This observation does not necessarily support the case that CTC 
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decreases 5’-deiodinase activity and may, on the surface, support the idea that CTC may 
have enhanced the T3 response in the absence of implant. 
When the T3 and T4 results in the current experiment are compared with previous 
research, some inconsistencies are apparent.  First, previous research has shown 
Synovex-S® to have either no effect on area under the response curve or to decrease 
circulating T3 (Rumsey et al., 1997; Kahl et al., 1992).  These results are in conflict with 
the current experiment, in which the response of T3 was greater for steers receiving an 
estrogenic implant.  Second, a discrepancy between our data and previous literature is the 
failure to demonstrate an effect of CTC or implant on the T4 response to an injection of 
TRH + GHRH.  Rumsey et al. (1999d) demonstrated that CTC decreased magnitude of 
the T4 response to a TRH + GHRH challenge, while other research has shown that 
Synovex-S® increased circulating concentrations of T4 in plasma from blood samples 
collected 60 d post-implantation or in 2-wk intervals for 56 d, respectively (Kahl et al., 
1978; Gopinath and Kitts, 1984).  Rumsey et al. (1997) demonstrated an increased T4 
response to a TRH + GHRH challenge in Synovex-S® implanted compared to non-
implanted steers.  The experiments of Rumsey et al. (1997, 1999) allowed development 
of more complete T4 response curves than the current experiment in which T4 
concentrations continued to rise 360 min post-challenge.  Two plausible mechanisms 
could explain the observed response.  First, Larsen (2003) suggests that when a TRH 
challenge is given, T4 concentrations may not change, because the circulating pool of T4 
is large and an increase in release may be too small to detect.  Approximately 70% of 
circulating T4 is bound to thyroid-binding globulin and other proteins, while the 
remaining 30% circulates in a free form and is considered to be the “metabolically 
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active” pool (Larsen 2003).  This ratio of bound:free T4 is tightly regulated and difficult 
to alter, therefore the response of T4 to hormonal treatments such as estrogen implants 
may be highly variable between experiments.  Secondly, the half-life of T4 is 6.7 d; 
therefore, because the thyroid is a significant reservoir of T4, the variability in release 
rate after a TRH challenge combined with a long half-life may delay the achievement of a 
complete response curve.  If blood had been collected past 360 min in the current 
experiment, e.g., 480 and 600 min, T4 plasma concentrations may have begun to decline 
within those time periods. 
Effects of Estrogenic Implant on Anabolic Hormones and Body Weight Gain   
 Although previous research has demonstrated that anabolic implants enhance BW 
gain through increases in protein accretion, the modes of action have not been clearly 
identified.  Some research involving estrogenic implants has focused on the roles of 
pituitary hormones such as GH and TSH (Gopinath and Kitts, 1984a; Loy et al., 1988a; 
Kahl et al., 1992; Aldrich et al., 1996; Rumsey et al., 1996, 1997); however, no research 
has examined the response of GH and thyroid hormones to a releasing hormone challenge 
at multiple time-points over an entire finishing phase.  Clearly, the lack of treatment x 
day interactions in the current experiment showed that the response of GH and thyroid 
hormones to TRH + GHRH injection was greater for implanted compared to non-
implanted steers throughout the experiment, and the enhanced response of these 
hormones appeared to be associated with an overall increase in BW gain for the 
implanted compared to non-implanted steers.  However, the most significant 
enhancement in BW gain was observed for these steers only in the periods immediately 
following implantation (d 0-26 and d 55-82).  Thus, increased BW gain may not be 
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consistently associated with heightened sensitivities of the pituitary and thyroid glands in 
steers receiving estrogenic implants, as assessed by the releasing-hormone challenges.  
Additionally, our data show that the overall GH response in the implanted steers was 
greater compared to the non-implanted steers.  Our data also support the notion that the 
releasable GH pool may have been greater for the implanted animals, and the pool of 
TSH and T3 was greater for steers receiving Synovex-S®.  It is important to note that 
estrogenic implants may have a direct effect on skeletal muscle protein synthesis due to 
the presence of high-affinity, estrogen receptors, which have been identified in bovine 
skeletal muscle (Meyer and Rapp, 1985; Sauerwein and Meyer, 1989).  The most likely 
mode of action for the increased protein accretion observed with the administration of 
estrogenic implants is a combination of increased GH and thyroid hormone secretion 
rates, as well as some direct effects of the estrogen on skeletal muscle cells. 
 In conclusion, Synovex-S® enhanced GH and thyroid hormone status across all 
measured time-points and increased overall rate and efficiency of BW gain over the 112-
d finishing period. However, improvements in growth performance were not consistent 
with the increase in pituitary and thyroid hormones throughout individual periods of the 
experiment.  Although there were no main effects of CTC on pituitary or thyroid 
hormones, or tissue accretion, CTC x estrogenic implant interactions were observed for 
T3, and perhaps carcass protein and fat accretion, suggesting that CTC may mitigate the 
effects of implant in beef cattle during the feedlot finishing phase of production. 
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 Table 3.1  Step-up and experimental diets 
 Step-Up Step-Up Experimental Experimental 
Ingredient, % DM Diet #1 Diet #2 Diet (d -10-56) Diet (d 57-112) 
Corn silage 20.00   5.00 ----- ----- 
Alfalfa haylage 20.00 20.00 20.00 20.00 
Cracked corn 50.00 65.00 70.00 70.00 
Corn gluten meal   2.97   2.97  2.97 ----- 
Ground corn   4.78   4.78  4.78  7.75 
Urea   0.36   0.36  0.36  0.35 
Limestone   1.07   1.07  1.07  1.07 
Trace mineral-salt1   0.51   0.51  0.51  0.51 
Vitamins A, D, E2   0.02   0.02  0.02  0.02 
Choice white grease   0.31   0.31  0.31  0.30 
1  98.5% NaCl, 0.35% Zn, 0.34% Fe, 0.20% Mn, 330 ppm Cu, 70 ppm I,  
50 ppm Co, 90 ppm Se    
2  8,800 IU/g vitamin A, 1,760 IU/g vitamin D, 1.1 IU/g vitamin E 
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Table 3.2  Effects of oral chlortetracyclinea (CTC) and growth implant on  
body weight gain, feed intake, and efficiency of gain 
 -Implant  +Implant  P < 
Item -CTC +CTC   -CTC +CTC SEMb CTC Implant Xc 
Period 1, 0-26 d          
   Initial BW, kg 363 366  369 363 21.03 0.90 0.85 0.62 
   DMI, kg/d 9.60 9.13  9.13 9.04   0.98 0.50 0.51 0.66 
   Body weight gain, kg/d 1.88 1.89  2.21 2.34   0.33 0.60 0.01 0.70 
   Gain:DMI, g/kg 86.92 91.29  106.93 112.41   7.01 0.46   0.005 0.93 
          
Period 2, 27-54 d          
   Initial BW, kg 411 415  427 424 18.37 0.94 0.15 0.66 
   DMI, kg/d 10.21 9.72  10.33 9.32   1.24 0.17 0.79 0.62 
   Body weight gain, kg/d 1.49 1.61  1.91 1.58   0.33 0.45 0.19 0.12 
   Gain:DMI, g/kg 69.22 72.06  84.29 78.30   6.93 0.81 0.12 0.50 
          
Period 3, 55-82 d          
   Initial BW, kg 453 461  480 468 20.04 0.78 0.06 0.26 
   DMI, kg/d  9.27 9.66  10.15 9.11   1.46 0.61 0.79 0.26 
   Body weight gain, kg/d 1.07 1.43  1.78 1.59   0.45 0.66 0.03 0.16 
   Gain:DMI, g/kg 53.64 66.14  80.67 80.13   9.65 0.52 0.03 0.48 
          
Period 4, 83-110 d          
   Initial BW, kg 483 501  530 512 19.49 0.99   0.002 0.05 
   DMI, kg/d 9.83 9.84  10.42 9.75   1.21 0.52 0.63 0.52 
   Body weight gain, kg/d 1.36 1.40  1.55 1.49   0.36 0.94 0.37 0.72 
   Gain:DMI, g/kg 63.65 65.40  68.32 71.06   5.53 0.67 0.33 0.92 
          
0-110 d          
   Initial BW, kg 363 366  369 363 21.03 0.90 0.85 0.62 
   Final BW, kg 522 540  574 555 26.88 0.99 0.01 0.12 
   DMI, kg/d 9.73 9.59  10.02 9.31   1.05 0.35 0.99 0.53 
   Body weight gain, kg/d 1.42 1.57  1.87 1.74   0.24 0.93 0.01 0.17 
   Gain:DMI, g/kg 67.45 74.17   84.14 84.48   3.76 0.33   0.001 0.37 
aChlortetracycline was fed at 350 mg of CTC per day 
per steer       
bStandard error of the mean calculated from analysis of variance using n=5     
cInteraction of CTC x Implant          
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Chapter 4 
Experiment 2 
Effects of chlortetracycline (CTC) and Revalor-S® on growth performance and 
carcass quality traits of finishing beef steers 
 
Introduction 
 Subtherapeutic feeding of chlortetracycline (CTC) has been shown to have 
growth-promoting effects for ruminants, swine, and poultry, but the mechanisms 
responsible for these effects are not known.  Most hypotheses for growth promotion by 
antibiotics in ruminants relate to effects on digestive tract microorganisms or gut wall 
thinning (Visek, 1978).  Based on the effects of CTC on carcass composition of calves, it 
has been suggested that CTC may influence growth via an endocrine axis (Landagora et 
al., 1957).  Previously we have shown that chronic, oral administration of 350 mg CTC 
per steer per day elevated circulating IGF-1 (McLeod et al., 2003) concentrations and 
reduced plasma concentrations of growth hormone (GH), thyroid-stimulating hormone 
(TSH), and thyroxine (T4) following injection of thyrotropin-releasing hormone (TRH) 
and growth hormone-releasing hormone (GHRH) in beef steers (Rumsey et al., 1999c).  
Corresponding with these shifts in circulating hormone concentrations and sizes of the 
releasable pools were increases in both subcutaneous and intramuscular fat deposition 
(Rumsey et al., 2000).  However, more recently we showed that oral administration of 
CTC over a 112-d period did not attenuate the release of GH or TSH in response to TRH 
+ GHRH challenges conducted at d 30, 56, and 106 and although CTC had no effect on 
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subcutaneous fat deposition, intramuscular fat deposition tended to be greater in CTC-fed 
steers (Kitts et al., 2007). 
 Implants containing estradiol and either progesterone or trenbolone acetate are 
used in finishing beef steers to improve feed efficiency and enhance lean tissue growth.  
Research has indicated increases in hot carcass weight (HCW), improved average daily 
gain (ADG) and feed efficiency, as well as greater longissimus dorsi areas with the use of 
anabolic implants in finishing programs for beef cattle (Perry et al., 1991; Herschler et 
al., 1995; Johnson et al., 1996; Hermesmeyer et al., 2000; Platter et al., 2003).  However, 
it has also been demonstrated that marbling scores are lower for cattle receiving growth 
implants, resulting in a lower percentage of carcasses grading Choice (Hermesmeyer et 
al., 2000; Platter et al., 2003).  Current carcass pricing grids provide incentive for the 
development of nutritional strategies to improve the carcass grades of finished cattle from 
Select to Choice (Select = slight amount of intramuscular fat, Choice = moderate amount 
of intramuscular fat; McKenna et al., 2002).   
 Although research has shown effects of CTC and anabolic implants on growth in 
cattle, there is a paucity of information on effects of CTC on growth performance and 
carcass characteristics when fed in conjunction with anabolic implants.  Therefore, the 
objective of the current experiment was to determine if CTC and an anabolic implant 
containing estradiol benzoate + trenbolone acetate interact to affect growth performance 
and carcass characteristics of finishing beef steers.  Specifically, we challenged the 
proclivity of CTC to promote marbling using an aggressive implant strategy that would 
enhance protein accretion and tend to oppose intramuscular fat deposition. 
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Materials and Methods 
Animals and Treatments   
 The protocol for the research discussed in this report was approved by the 
University of Kentucky Institutional Animal Care and Use Committee.  Ninety-six 
English-Continental crossbred steers were purchased from a commercial sale yard in 
Central Kentucky.  After arriving at the University of Kentucky Animal Research Center, 
steers were dewormed using ivermectin (Merial, Duluth, GA), and vaccinated using 
Bovi-Shield™4 and Ultrabac®7 (Pfizer Animal Health, Exton, PA).  Steers were housed 
in group pens (5 steers per pen) for a 56-d backgrounding period during which they had 
ad libitum access to a 65:35 concentrate-forage diet. The group pens measured 14.6 x 2.4 
m and were located on a concrete pad partially covered with a roof.  The steers had 
continuous access to automatic waterers. 
 After the backgrounding period, steers were limit-fed two transition diets for an 
additional 30 d at 90% of the previous ad libitum intake.  These transition diets consisted 
of 75:25 and 85:15 concentrate-forage, respectively, and were fed for adjustment to ad 
libitum intake of the experimental diet (Table 4.1).  Ad libitum intake of the experimental 
diet was established incrementally over a 7-d period during the transition period, 
immediately prior to beginning the experiment.  Steers were blocked by body weight 
(BW; 6 blocks), assigned randomly to pen within their respective block, and pens were 
assigned randomly to a 2 x 2 factorial arrangement of treatments within block.  
Treatments included feed containing either 0 or 39.6 ppm (DM basis) CTC (Aureomycin, 
Alpharma Animal Health, Fort Lee, NJ) and Revalor-S® or no Revalor-S® (120 mg 
trenbolone acetate + 24 mg 17-β estradiol benzoate, Intervet Inc., Millsboro, DE).  The 
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level of CTC used in this study provided approximately 350 mg CTC/steer/d and was the 
same as the level used in previous experiments by Rumsey et al. (1999c, 2000) and Kitts 
et al. (2005, submitted).  Steers assigned to receive Revalor-S® were implanted on d 1 
and re-implanted on d 63.  The experimental diet was formulated using two protein 
supplements:  Protein supplement 1 was formulated to provide 105% of the 
metabolizable protein (MP) requirement for large-frame steers (345 kg BW) gaining 1.60 
kg/d and was fed until d 63 of the experiment; Protein supplement 2 was formulated to 
provide 105% of the MP requirement for large-frame steers (450 kg BW) gaining 1.20 
kg/d and was fed from d 63-125 or 139 (NRC, 2000).  Steers were fed daily at 0900.  
Once weekly, orts were measured and the amount of feed offered was adjusted to 
maintain approximately 10% orts.  Individual diet ingredients were sampled weekly and 
analyzed for DM content.  Weekly determinations of DM content were used in the 
adjustment of the amount of feed offered the following week.   
 Body weights were measured every 28 d before feeding.  Initial and final BW 
were determined by weighing steers on two consecutive days.  Ultrasound was used on a 
subset of steers (approximately 8-10 steers) from the heaviest blocks (Blocks 5 & 6) to 
determine the amount of subcutaneous fat over the 12th rib on d 118.  Because these 
steers met or exceeded 12 mm of backfat, it was determined that they had completed the 
finishing phase.  On d 125, these steers were transported to a commercial slaughter 
facility and killed the following day.  Subsequently, the remaining 4 blocks of steers 
completed the finishing phase on d 139 and were killed on d 140.  A merit evaluation of 
each carcass was done according to USDA standards and performed by a qualified meat 
scientist the following day.  Carcass quality indicators were longissimus muscle area, fat 
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over longissimus muscle, kidney, pelvic, and heart fat (KPH), marbling, and bone 
maturity.   
Statistical analyses   
 Growth performance and carcass data were statistically analyzed by analysis of 
variance for a randomized complete block (weight) design with a 2 x 2 factorial 
arrangement of treatments using PROC GLM procedures of SAS (SAS Inst., Inc., Cary, 
NC, 2003).  Pen was the experimental unit and the model included block, CTC, implant, 
and the interaction of CTC and implant. All blocks of animals were used for growth 
performance calculations through d 125, while only blocks 1-4 were used for growth 
performance calculations from d 126-139 (blocks 5 &6 were killed on d 126).  When 
interactions were significant (P ≤ 0.10), protected Fisher’s LSD were used to separate 
effects of implant within each level of CTC. 
 
Results 
Growth Performance   
 Average daily gain, dry matter intake (DMI), and efficiency of gain (BW gain per 
unit of DMI) are summarized in Table 4.2.  Over the course of the entire experiment (d 0-
139), CTC reduced (P = 0.02) DMI by 0.4 kg/d compared to steers receiving no CTC, 
while implanted steers gained 0.4 kg/d more (P = 0.0001) BW than non-implanted steers.  
Overall, there was an interaction (P = 0.03) between CTC and implant for efficiency of 
gain.  In the absence of CTC, implanted cattle gained 31% more efficiently than non-
implanted cattle, whereas in the presence of CTC, implant only resulted in a 20% 
increase in feed efficiency (P < 0.0001).   
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 During the early part of the finishing phase (d 0-84), Revalor-S® increased ADG 
and efficiency of gain 25% and 26%, respectively, above that of non-implanted steers (P 
≤ 0.01).  During periods of this same phase, implant and CTC decreased DMI by an 
average of 0.5 kg/d (d 0-28 and d 29-56, respectively; P ≤ 0.05).  The decrease in DMI 
did not affect (P = 0.83) efficiency of gain for the steers fed CTC (d 29-56).  There was 
an increase (P = 0.01) in ADG for the implanted steers (d 0-28). There were no effects (P 
≥ 0.13) of CTC on ADG or efficiency of gain during the rest of this phase. 
 During the latter part of the finishing phase (d 85-139), interactions occurred 
between CTC and implant (P ≤ 0.07) for ADG and efficiency of gain.  In the absence of 
CTC, implanted steers gained an average of 0.74 kg/d more than non-implanted steers (P 
= 0.007), but in the presence of CTC, implant had no effect (P ≥ 0.13).  Additionally, 
there was a significant (P ≤ 0.07) interaction between CTC and implant for efficiency of 
gain.  In the absence of CTC, implanted steers gained 60% more efficiently than non-
implanted steers (P ≤ 0.02); however, implant had no effect (P ≥ 0.31) in the presence of 
CTC.  Additionally, DMI tended to increase (P ≤ 0.06) by 0.84 kg/d for implanted 
compared to non-implanted steers.  Chlortetracycline had no effect (P ≥ 0.28) on DMI 
during this phase of finishing. 
     Carcass Quality.  There were no interactions (P ≥ 0.53) between CTC and implant for 
carcass quality measures (Table 4.3).  There were no effects (P ≥ 0.22) of treatment on 
longissimus dorsi area or fat cover, KPH fat, marbling, or yield grade.   
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Discussion 
 The objective of the current experiment was to determine if CTC and an anabolic 
implant containing estradiol benzoate + trenbolone acetate interact to affect growth 
performance and carcass characteristics of finishing beef steers.  Because it has been 
demonstrated that CTC has the ability to increase subcutaneous and intramuscular fat 
deposition (Bohman and Wade, 1958; Harvey et al., 1968; Rumsey et al., 2000) and 
anabolic implants containing trenbolone acetate + estradiol benzoate have been shown to 
reduce marbling score and the percentage of carcasses grading Choice (Hermesmeyer et 
al., 2000; Platter et al., 2003), it is of interest to determine if CTC can transcend the 
antagonistic effects of an anabolic implant and increase the deposition of intramuscular 
fat.  Over the course of the entire experiment, implanted steers had greater ADG; 
however, an interaction between CTC and implant for feed efficiency revealed that the 
presence of CTC slightly attenuated the response to implantation.  Furthermore, this 
interaction was a result of treatment effects that occurred late in the finishing period, 
specifically in the last 27 d.   There were no effects of CTC or Revalor-S® on carcass 
characteristics, most notably those involving fat deposition.  These results are 
inconsistent with our hypothesis, considering that previous research has shown CTC and 
Revalor-S® to positively and negatively affect fat deposition, respectively.   
Growth Performance   
 It is a common practice to implant cattle in the finishing phase of growth using 
different ratios of estradiol benzoate and trenbolone acetate, depending on stage of 
finishing (e.g., d 1-70 vs. d 71-140).  These combinations of estrogens and androgens 
account for an additive growth response in cattle, commonly increasing ADG and 
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improving feed efficiency above those of cattle receiving estrogenic implants alone 
(Hershler et al., 1995).  Although the mechanism for such increases in ADG and feed 
efficiency remains somewhat ambiguous, it is known that androgens possibly inhibit 
release of hormones that cause muscle degradation, thus increasing protein accretion 
above that of estrogenic implants alone (Solis et al., 1989).  In the current experiment, it 
was expected that implant would positively affect ADG, which increased approximately 
28% compared to non-implanted steers.  This finding agrees with previous research using 
trenbolone acetate + estradiol benzoate implants in which ADG increased 21% in 
implanted steers approximately 127 d on feed (Perry et al., 1991; Mader et al., 1994; 
Johnson et al., 1996; Hermesmeyer et al., 2000).  Additionally, this improvement in ADG 
was considerably greater than the 16% increase in ADG of steers implanted with 
progesterone + estradiol benzoate (Synovex-S®) in previous studies averaging 108 d 
(Rumsey et al., 1992, 1999a; Mader et al., 1994; Hermesmeyer et al., 2000).  These data, 
in conjunction with previous research, indirectly support the idea that implants containing 
trenbolone acetate + estradiol benzoate improve ADG to a greater extent than those 
containing progesterone + estradiol benzoate.     
 In part, the overall increase in ADG for the current experiment was due to an 
improvement in ADG of 25% for cattle receiving Revalor-S® during the initial 84 days.  
However, in the absence of CTC, there was a greater improvement in ADG (71%) for 
implanted compared to non-implanted steers during the final 55 days of the finishing 
phase.  These results demonstrate that not only did Revalor-S® increase ADG above that 
of non-implanted steers during the early phases of finishing, but the improvements were 
even more dramatic during the latter phase of finishing, considering that non-implanted 
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cattle normally deposit adipose tissue as a greater proportion of empty body gain during 
this time (Byers 1982; Owens et al., 1995).  Furthermore, other research has shown that 
steers receiving a synthetic androgen plus estradiol had increased protein and less fat in 
their final empty body gain (Solis et al., 1989), suggesting a greater priority for lean 
tissue growth with an anabolic implant.  Although protein accretion was not measured 
directly in the current experiment, the improvement in ADG for implanted steers 
observed throughout this experiment suggest that the combination of androgen and 
estrogen may have increased protein accretion, possibly by repartitioning compositional 
gain away from fat and towards protein deposition in this group of animals (Herschler et 
al., 1995; Solis et al., 1989).  Although the mechanism explaining lower ADG for steers 
receiving CTC in the presence of implant is unknown, an explanation may be related to 
thyroid hormone function.  Rumsey et al. (1999c) demonstrated that subtherapeutic 
administration of CTC decreased GH and thyroid hormone responses to a TRH + GHRH 
challenge in growing steers over a 91-d period.  More recently, Kitts et al. (2007) showed 
a greater triiodothyronine (T3) response for steers implanted with Synovex-S® (200 mg 
progesterone + 20 mg 17-β estradiol benzoate) than those receiving no implant in the 
absence of CTC.  Triiodothyronine was not affected by implant in the presence of CTC.  
Although the implant used contained progesterone + estradiol benzoate, in the current 
experiment it is possible that, at least during the final period, the decrease in ADG for 
non-implanted and implanted steers in the presence of the CTC may have been associated 
with decreased thyroid function through an unknown mechanism which subdued the rate 
of BW gain. 
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 Chlortetracycline and implant interacted to affect efficiency of gain for the entire 
experiment (d 0-139).  Implanted steers gained more efficiently both in the absence and 
presence of CTC; however, the improvement in efficiency of gain for implanted steers in 
the presence of CTC was only 20%, compared to a 31% increase in the absence of CTC.  
This finding suggests that CTC may have attenuated an improvement in efficiency of 
gain for implanted steers.  Furthermore, this decrease in efficiency of gain is a function of 
the numerically lower ADG for implanted steers in the presence of CTC.  Although it is 
not altogether surprising that in the absence of implant, CTC had no positive effect on 
ADG and efficiency of gain as we have previously shown no effect of CTC these 
parameters (Kitts et al., 2007), it is a unique observation that the improved efficiency of 
gain for implanted steers was slightly diminished in the presence of CTC.  This 
interaction between CTC and implant regarding efficiency of gain results from similar 
interactions that occurred late in the finishing phase (d 85-139); there was an increase in 
efficiency of gain for steers implanted in the absence, but not presence, of CTC.  It is 
possible that the lower efficiency of gain occurring in the presence of CTC and implant 
during the last 27 d was due to both an increase in DMI for implanted steers (P = 0.005) 
and no positive effect of implant on ADG in the presence of CTC (P = 0.79).   
 Although there was no effect of CTC on most parameters of growth during the 
finishing phase, DMI decreased an average of 0.4 kg/d for steers fed CTC compared to 
steers receiving no CTC.  The reason for this decrease in intake is unclear; previous 
studies which included oral, subtherapeutic levels of CTC in the diets of finishing steers 
and lambs showed no effect of CTC on DMI (Erwin et al., 1956; Bolsen et al., 1968).  
Although the steers receiving CTC in the current experiment consumed less during 
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Period 2, this decrease in intake did not translate to a significant reduction in ADG or 
efficiency of gain.  The effects of subtherapeutic, oral administration of CTC on ADG 
and efficiency of gain have been shown to be variable.  Earlier research has demonstrated 
increased BW gain and efficiency in growing but not finishing steers, whereas other data 
suggests improvements in weight gain for feedlot steers (Perry et al., 1954; Brown et al., 
1975).  The lack of effect of CTC on ADG and efficiency of gain seen in the current 
experiment has also been observed in previous experiments by Rumsey et al. (2000) and 
Kitts et al. 2007).  Although the reason for these discrepancies is unclear, it has been 
suggested that the effects of CTC on growth performance are more apparent under 
stressful conditions that are immunologically challenging to the animal (Visek, 1978).  In 
both the current study and those of Rumsey et al. (2000) and Kitts et al. (2007), steers 
were vaccinated and backgrounded for a minimum of 30 d, and adjusted to the 
experimental diet prior to initiation of the experiment.                                                                    
Carcass Quality 
 In previous research involving anabolic implants containing trenbolone acetate + 
estradiol benzoate, the effects of this implant on carcass characteristics have been 
variable; however, most research has shown that an implant containing estrogen + a 
synthetic androgen such as trenbolone acetate negatively affects marbling score and 
often, decreases the percentage of carcasses grading Choice (Hermesmeyer et al., 2000; 
Roeber et al., 2000; Reiling and Johnson, 2003).  Although monetary benefit is realized 
through an increase in ADG and feed efficiency with these anabolic implants, a decrease 
in marbling and thus, lowering quality grade from Choice to Select reduces the value of a 
carcass.  Therefore, it is of interest to develop strategies which allow producers to benefit 
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from improved ADG and feed efficiencies associated with growth implants, while finding 
other compounds capable of improving marbling scores in concert with implants.  The 
results of the current experiment showed a lack of change in longissimus area or fat cover 
and marbling and therefore reflects no effect of implant on compositional gain.  
However, these results do not preclude the possibility that compositional gain was altered 
during Period 4 (d 85-112), when an interaction between CTC and implant occurred for 
ADG.  There was no effect of implant or CTC on the remaining carcass characteristics.  
These results disagree with most previous research showing lower marbling scores and 
percentage of carcasses grading Choice in steers implanted with Revalor-S® (Mader et 
al., 1994; Hermesmeyer et al., 2000; Roeber et al., 2000; Reiling and Johnson, 2003).  
Conversely, CTC fed to steers has increased longissimus fat cover and numerically 
increased marbling scores (Rumsey et al., 2000) and increased the number of carcasses 
grading Choice (Perry et al., 1958).  Furthermore, longissimus muscle area has been 
shown to be greater when Revalor-S® was used in finishing cattle (Johnson et al., 1996; 
Hermesmeyer et al., 2000; Roeber et al., 2000).  Interestingly, none of these effects were 
seen in the current experiment demonstrating that, at least in this group of animals, 
Revalor-S® did not negatively, and CTC did not positively, affect carcass quality.   
 In summary, Revalor-S® increased ADG over the course of the finishing period 
as expected; however, the positive effect of implant on feed efficiency was partially 
attenuated in the presence of CTC.  This attenuation appears to be a function of both DMI 
and ADG.  Although CTC reduced DMI, the putative mechanism responsible for this 
interaction is unclear; it appears to be manifested through changes in both DMI and 
ADG, neither of which are mutually exclusive variables.  Additionally, inconsistent with 
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previous observations, carcass quality traits in the current experiment were not affected 
by either Revalor-S® or CTC.  Because Revalor-S® did not negatively affect carcass 
quality, this shows that growth implants containing estrogen + synthetic androgens 
positively affect growth performance, while not discounting carcass value.  These data 
clearly illustrate the need for further research to identify potential interactions between 
anabolic implants and CTC regarding feedlot performance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experiment 2 has been previously published in the Journal of Animal and Veterinary 
Advances in 2006, Volume 5, pages 70-76.
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Chapter 5 
Experiments 3 & 4 
 
Effects of dexamethasone administration and Revalor-S® 
on growth, carcass characteristics and visceral organ and fat mass of finishing 
beef steers 
 
Introduction 
  Dexamethasone (DEX) is a synthetic glucocorticoid which acts as an anti-
inflammatory agent and immunosuppressant.  Dexamethasone has been used extensively 
in research experiments, particularly to study glucose metabolism in both animals and 
humans (Plested et al., 1987; Vernon and Taylor, 1988; Matsumoto et al., 1996; Schneiter 
and Tappy, 1998).  Many studies also suggest that DEX stimulates fatty acid synthesis in 
the liver, subcutaneous and visceral (omental) fat depots in both mice and humans 
(Dolinsky et al., 2004; Gounarides et al., 2008; Wang et al., 2004).   
Limited research has been conducted in ruminants regarding the use of DEX to 
study glucose metabolism or manipulate fat deposition.  A study by Brethour (1972) was 
performed in response to the observation that foundered cattle treated with DEX tended 
to have higher carcass grades.  In Brethour’s experiment, cattle were injected 
intramuscularly (IM) with 10 mg of DEX 132, 90, 76 or 33 d prior to slaughter.  When 
cattle were injected with DEX 90, 76 or 33 d prior to slaughter, marbling score, a 
measure of intramuscular fat, was improved.  These results certainly suggest that single 
injections of DEX prior to slaughter have the potential to increase intramuscular fat in 
finishing beef cattle, thus increasing carcass value and producer profit. 
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 Implants containing trenbolone acetate and estradiol are routinely used in 
finishing beef cattle to enhance lean tissue deposition and improve feed efficiency.  
Research has indicated increases in hot carcass weight, improved average daily gain 
(ADG) and feed efficiency, as well as greater longissimus dorsi areas with the use of 
anabolic implants in finishing programs for beef cattle (Perry et al., 1991; Herschler et 
al., 1995; Johnson et al., 1996; Hermesmeyer et al., 2000; Platter et al., 2003).  However, 
it has also been demonstrated that marbling scores are lower for cattle receiving growth 
implants, resulting in a lower percentage of carcasses grading Choice (Hermesmeyer et 
al., 2000; Platter et al., 2003).  Because of the negative effects growth implants can have 
on marbling scores, there is an incentive to development nutritional strategies to improve 
carcass quality grades of finishing cattle from Select to Choice. 
 Because of the lack of research regarding the use of DEX in finishing beef cattle 
to possibly improve marbling when used in conjunction with growth implants, the 
objective of the current experiments was to assess the effects of DEX injections in the 
presence and absence of growth implant on growth performance, carcass quality, omental 
and mesenteric fat depots, and organ weights.  We hypothesized that DEX injections 
would increase marbling and the amount of omental and mesenteric fat; however, we 
hypothesized that the addition of growth implant may mitigate this response. 
 
Materials and methods 
The animal procedures for the research discussed in this report were approved by 
the University of Kentucky Institutional Animal Care and Use Committee. 
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Experiment 3 
Animals and Treatments   
   One hundred forty-four Angus crossbred steers were purchased from a 
commercial sale yard in Central Kentucky.  After arriving at the University of Kentucky 
Animal Research Center, steers were treated for elimination of internal parasites 
(Ivermectin, Merial, Duluth, GA) and vaccinated (Bovi-Shield™4 and Ultrabac®7, 
Pfizer Animal Health, Exton, PA).  Before commencement of the experiment, steers were 
housed in group pens and received two transition diets which consisted of 70:30 and 
80:20 concentrate:forage ad libitum, respectively.  Each diet was fed for 7 d.  Ad libitum 
intake of the experimental diet (Table 5.1) was established incrementally over a 7-d 
period prior to beginning the experiment.  Group pens measured 14.6 x 2.4 m and were 
located on a concrete pad partially covered with a roof.  The steers had continuous access 
to automatic waterers. 
 Steers were blocked by BW (4 blocks; 428 kg ± 4), assigned randomly to pen 
within their respective block, and pens were assigned randomly to a 2 x 2 factorial 
arrangement of treatments within block.  Treatments included either no implant or 
Revalor-S® (120 mg trenbolone acetate + 24 mg 17-β estradiol benzoate, Intervet 
International, Millsboro, DE) on d 1 and either no or i.m injections of 0.09 mg/kg BW 
DEX on d 1, 28, and 56.  All cattle were moved to the handling facility for weighing on d 
0, 1, 28, 56 and 83 prior to feeding.  In order to avoid a singe injection site, DEX was 
injected into the right gluteus medius muscle on d 1, the right trapezius muscle on d 28 
and the left trapezius muscle on d 56.  The level of DEX used in Exp. 3 & 4 was based on 
a previous experiment in which a single dose (i.m.) of 0.05 mg/kg BW DEX administered 
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90, 76 or 33 d prior to slaughter increased marbling in finished beef cattle (Brethour 
1972). 
 Steers were fed daily at 0900.  Once weekly, orts were measured and the amount 
of feed offered was adjusted to maintain approximately 10% orts.  Individual diet 
ingredients were sampled weekly and analyzed for DM content (AOAC, 1984).  Weekly 
determinations of DM content were used in the adjustment of the amount of feed offered 
the following week.   
 On d 83, all steers were weighed to obtain a final BW.  Slaughter weights were 
obtained by weighing steers on either d 84 or 86 immediately prior to slaughter.  One 
hundred twelve steers were transported to a commercial facility and slaughtered on d 84.  
A merit evaluation of each carcass was done according to USDA standards and 
performed by a qualified meat scientist the following day.  Carcass quality indicators 
were longissimus muscle area, fat over longissimus muscle, kidney, pelvic and heart fat 
(KPH) and marbling. 
Blood Glucose Analyses 
 On d 1, 28, 56 and 83, blood samples were collected from the jugular vein for 
determination of whole blood glucose concentration.  Samples (10 mL) were collected in 
heparinized sample tubes (Vacutainer, Fisher Health Care, Chicago, IL) and immediately 
placed on ice.  Within 2 h of collection, all samples were analyzed for whole blood 
glucose using a membrane-immobilized enzyme system (YSI Model 2700, Yellow 
Springs Instrument, Inc., Yellow Springs, OH).   
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Visceral Organs and Tissues 
Eight steers/block,8 steers/treatment, were selected to be slaughtered on d 84 or 
86 in the University of Kentucky abattoir for determination of organ and alimentary fat 
mass.  This selection was based on representation of the final average BW for each 
treatment within each block.  On each slaughter day, all treatments were represented and 
the order of animal slaughters was randomized to avoid bias of treatment order.  Steers 
were stunned with a captive bolt gun, exsanguinated, and viscera removed and placed 
into a visceral cart for separation.  The pyloric valve and ileo-cecal junction were 
identified and the proximal and distal ends of the small intestine were ligated prior to 
separation to prevent contamination of tissues, particularly adipose, with digesta contents.  
Forestomachs (rumen + reticulum and omasum + abomasum) were separated from 
connective and omental adipose tissue, digestive contents emptied, rinsed with warm tap 
water, blotted, and weighed.  Omental adipose tissue was quantitatively collected, rinsed 
with warm tap water, blotted, and weighed. 
The liver was removed, trimmed of connective tissue, weighed and sampled using 
a stainless steel trocar (12 mm internal diameter).  In order to obtain a representative 
sample, three cross sections (460 mm x 12 mm) were acquired commencing at the right 
lobe and concluding at the left lobe of the liver.  These samples were pooled, placed in a 
foil bag, snap-frozen in liquid nitrogen and stored at -80˚C until analyses.  Subsequently, 
samples were freeze-dried for 3 d using a Model 18 DX48SA “Keepsake Specialist” 
freeze dryer (Botanique Preservation Equipment, Inc., Peoria, AR).  Percentage dry 
matter of the samples was determined using sample weight before and after freeze-
drying.  Prior to ether extraction (EE), samples were ground using a mortar and pestle.  
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Dried samples were weighed (approximately 1 g) in duplicate and extracted for 1 h using 
petroleum ether in a Soxtec System HT extraction unit (Foss Tecator AB, Hoeganaes, 
Sweden).  The extracted fats were dried and weighed to determine liver fat content 
(AOAC, 1990) and expressed as a percentage of fresh weight.   
The small and large intestines were grossly separated from the mesentery and 
mesenteric adipose tissue and weighed.  Digestive contents of the small and large 
intestines were emptied and the tissues rinsed with warm tap water, blotted and weighed.  
Small intestines (SI) and large intestines (LI) with the remaining attached mesenteric 
adipose tissue were frozen in separate plastic bags for subsequent freeze-grinding and 
analysis of EE.  Small and large intestines were freeze-ground three times through a 0.6 
cm screen using an Autio Grinder (Model 801GH50T, Autio Company, Astoria, Oregon).  
Each sample was ground with approximately 2 kg dry ice.  Wet samples were weighed 
(approximately 7 g) in duplicate and extracted for 1 h using petroleum ether for 
determination of fat content.  The following calculation was used to determine total 
mesenteric fat (kg):   
[(SI EE%) x (SI wt + associated fat)] + [(LI EE%) x (LI wt + associated fat)] + 
weighed mesenteric fat at slaughter (kg) = total mesenteric fat (kg)  
The following calculation was used to determine SI and LI weight:   
(Intestinal segment  EE%) x (Intestinal segment  wt + associated fat) = measured 
intestinal segment-associated mesenteric fat   
(Intestinal segment  wt + associated fat) – (measured intestinal segment-
associated mesenteric fat) = Intestinal segment  weight (kg) 
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The day following slaughter, longissimus dorsi samples were removed from the 
area between the 12th and 13th ribs for quantitative determination of intramuscular fat.  
Samples were trimmed of excess fat and other adjoining muscle, cut to a thickness of 
2.54 cm, weighed and frozen at -20˚C.  Frozen samples were ground twice at an ambient 
temperature of 0˚C using a mixer (KitchenAid® Model KSM150PS, St. Joseph, MI) with 
a food grinder attachment.  Wet samples were weighed (approximately 7 g) in duplicate 
and extracted for 1 h using petroleum ether for determination of fat content. 
Experiment 4 
Animals and Treatments 
 Ninety-six Angus crossbred steers were purchased from a commercial sale yard in 
Central Kentucky.  After arriving at the University of Kentucky Animal Research Center, 
steers were treated for elimination of internal parasites (Safe-Guard®, Intervet 
International, Millsboro, DE) and vaccinated (Vista®5 VL5 SQ and Vision®7 with 
Spur®, Intervet International, Millsboro, DE).  Similar to Exp. 3, steers were housed in 
group pens and received two transition diets which consisted of 70:30 and 80:20 
concentrate:forage ad libitum, respectively.  Each diet was fed for 7 d.  Ad libitum intake 
of the experimental diet (Table 5.1) was established incrementally over a 7-d period prior 
to beginning the experiment.  The diet used in Exp. 4 consisted of 80% cracked corn vs. 
80% high moisture corn in Exp. 3.  Because it has been shown that an isoenergetic, post-
ruminal infusion of starch or glucose increases fat deposition in ruminants, it was 
hypothesized in the current experiment that feeding a diet high in post-ruminal starch 
would increase fat deposition (McLeod et al., 2001; McLeod et al., 2007). 
103 
 
Group pens measured 14.6 x 2.4 m and were located on a concrete pad partially covered 
with a roof.  The steers had continuous access to automatic waterers.  Steers were 
blocked by BW (3 blocks; 385 kg ± 1), assigned randomly to pen within their respective 
block, and pens were assigned randomly to a 2 x 2 factorial arrangement of treatments 
within block.  Treatments were the same as described for Exp. 3 with the following 
modification: DEX was injected into the right gluteus medius muscle on d 1, the right 
trapezius muscle on d 28, the left trapezius muscle on d 56 and the left gluteus medius 
muscle on d 84.  Also, the duration of Exp. 4 was 112 d vs. 84 d for Exp. 3. 
 Steers were fed daily at 0900.  Once weekly, orts were measured and the amount 
of feed offered was adjusted to maintain approximately 10% orts.  Individual diet 
ingredients were sampled weekly and analyzed for DM content.  Weekly determinations 
of DM content were used in the adjustment of the amount of feed offered the following 
week.  Body weights were measured every 28 d before feeding.  Initial and final BW 
were determined by weighing steers on two consecutive days.;  Slaughter weights were 
obtained by weighing steers on d 106, 107, 109, 112, 113, 114, 115, 118 or 119 
immediately prior to slaughter. 
 On d 112, 60 steers were transported to a commercial facility and slaughtered on 
d 113.  Merit evaluations of each carcass were performed as described for Exp. 3. 
Visceral Organs and Tissues 
Twelve steers/block (9 steers/trt) were selected to be slaughtered on d 106, 107, 
109, 112, 113, 114, 115, 118 or 119 in the University of Kentucky abattoir for 
determination of organ and alimentary fat mass.  To avoid potential bias of initial BW 
that likely occurred in Exp. 3, steers whose average BW was equal across treatments at 
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commencement of the experiment were selected.  All subsequent procedures related to 
visceral organs and tissues, were the same as for Exp. 3 with the following exception:  the 
spleen, kidneys, heart and lungs were trimmed of adipose and connective tissue and 
weighed. 
Statistical Analyses for Exp. 3 & 4 
 All growth performance, organ and fat mass data were statistically analyzed by 
analysis of variance for a 2 x 2 factorial arrangement of treatments and randomized 
complete block design using MIXED procedures of SAS (v9.1; SAS Inst., Inc., Cary, 
NC).  The experimental unit was pen for the growth performance data and animal for 
carcass, organ and fat mass data.  The statistical model included the fixed effect of 
treatments and the random effect of block.  The following linear model was used: 
Yijk = μ + DEXi + Implantj + (DEX)(Implant)ij + εijk 
where Yijk is the observed value for the kth replicate of the ith level of DEX and the jth 
level of implant, μ is the grand mean, DEXi is the fixed effect of the ith level of DEX, 
Implantj is the fixed effect for the jth level of implant, (DEX)(Implant)ij is the fixed 
interaction effect of the ith level of DEX with the jth level of implant and εijk is the random 
error associated with the Yijk experimental unit.  All carcass data were statistically 
analyzed by analysis of variance for a 2 x 2 factorial arrangement of treatments and 
randomized complete block split plot design using MIXED procedures of SAS (v9.1; 
SAS Inst., Inc., Cary, NC).  The statistical model included the fixed effects of treatment 
and the random effects of block and location.  The following linear model was used: 
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Yijkl = μ + Loci + DEXj + Implantk + (Block)(Loc)li + (Loc)(DEX)ij + (Loc)(Implant)ik + 
(DEX)(Implant)jk + (DEX)(Block)(Loc)jli + (Implant)(Block)(Loc)kli + 
(DEX)(Implant)(Block)(Loc)jkli + (Loc)(DEX)(Implant)ijk + εjkli 
where Yijkl is the observed value for the ith location and the lth block of the jth level of 
DEX and the kth level of implant, μ is the grand mean, Loci is the random effect 
associated with the ith location, DEXj is the fixed effect associated with the jth level of 
DEX, Implantk is the fixed effect associated with the kth level of Implant, (Block)(Loc)li 
is the random interaction effect associated with the lth block of the ith location, 
(Loc)(DEX)ij is the random interaction effect associated with the jth level of DEX in the 
ith location,  (Loc)(Implant)ik is the random interaction effect associated with the kth level 
of implant in the ith location, (DEX)(Implant)jk is the fixed interaction effect associated 
with the jth level of DEX and kth level of implant, (DEX)(Block)(Loc)jli is the random 
interaction effect associated with the jth level of DEX and the lth block of the ith location, 
(Implant)(Block)(Loc)kli is the random interaction effect associated with the kth level of 
implant and the lth block of the ith location, (DEX)(Implant)(Block)(Loc)jkli is the random 
interaction effect associated with the jth level of DEX and the kth level of implant with the 
lth block of the ith location, (Loc)(DEX)(Implant)ijk is the random interaction effect 
associated with the jth level of DEX and the kth level of implant in the ith location and εjkli 
is the total random error associated with the Yijkl experimental unit.  Whole blood 
glucose concentrations were analyzed by analysis of variance for a 2 x 2 factorial 
arrangement of treatments and randomized complete block design with day as a repeated 
measure.  The following linear model was used:   
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Yijkl = μ + Blocki + DEXj + Implantk + (DEX)(Implant)jk + εijk + Dayl + (DEX)(Day)jl + 
(Implant)(Day)kl + (DEX)(Implant)(Day)jkl + εijkl 
where Yijkl is the observed value for the jth level of DEX and the kth level of implant in 
the ith block on the lth day, μ is the grand mean, Blocki is random effect of the ith block, 
DEXj is the fixed effect of the jth level of DEX, Implantk is the fixed effect for the kth 
level of implant, (DEX)(Implant)jk is the fixed interaction effect of the jth level of DEX 
with the kth level of implant, εijk is the error term for the jth level of DEX and the kth level 
of implant in the ith block, Dayl is the fixed effect of the lth day, (DEX)(Day)jl is the fixed 
interaction effect of the jth level of DEX on the lth day, (Implant)(Day)kl is the fixed 
interaction effect of the kth level of implant on the lth day, (DEX)(Implant)(Day)jkl is the 
fixed interaction effect of the jth level of DEX with the kth level of implant on the lth day 
and εijkl is the total error the jth level of DEX and the kth level of implant in the ith block 
on the lth day.  When interactions were significant (P ≤ 0.05), the slice option in the LS 
MEANS statement was used before pair-wise comparisons were made.  Additionally, the 
unbalanced number of observations (n=7; Imp + DEX) for pancreatic weight in Exp. 3 
reflects unrecorded data.  All data are presented as least square means ∀ SE, with the SE 
calculated using the least number of observations for each measured variable.  Treatment 
main effects and interactions were considered significant at P ≤ 0.05 and a tendency to be 
significant at P ≤ 0.10. 
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RESULTS 
Experiment 3 
Growth performance 
The effects of DEX injections and growth implant on BW gain, feed intake and 
efficiency of gain are shown in Table 5.2.  Over the course of the entire experiment, 
growth implant increased (P = 0.05) DMI by 4% relative to non-implanted steers.  This 
increase in DMI is representative of an average increase of 4.5% in Periods 1 and 3 for 
implanted compared to non-implanted steers.  There was an interaction (P = 0.05) 
between DEX and growth implant for ADG over 83 d.  In the presence of growth 
implant, DEX decreased (P = 0.003) ADG by 10% relative to the steers receiving no 
DEX.  There was no effect (P ≥ 0.10) of DEX in the absence of growth implant.  
Additionally, growth implant increased efficiency of BW gain (P = 0.0001) by 16% over 
steers with no growth implant.  These overall improvements in gain and efficiency are 
reflective of increased ADG and efficiency for implanted steers throughout each period 
of the experiment.  In Period 1, growth implant increased (P = 0.0001) ADG by 31% and 
efficiency of gain by 25% relative to steers receiving no implant.  In Periods 2 and 3, 
these improvements were an average of 16% and 11% for ADG and efficiency of gain, 
respectively. 
Contrary to the increase in efficiency of gain attributed to growth implant, DEX 
injections decreased (P = 0.02) efficiency over the course of the experiment by 5% 
compared to animals receiving no DEX.  This decrease in efficiency was manifested in 
both Periods 1 (P = 0.03) and 2 (P = 0.02) as 6% and 8%, for steers given DEX injections 
compared to no injections, respectively.  However, no effects (P ≥ 0.10) of DEX 
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injections on efficiency of gain were observed during the last 28 d of the feeding period.  
Regarding final BW, there was an interaction (P = 0.05) between DEX and growth 
implant.  As with ADG, in the presence of growth implant, DEX injections decreased (P 
= 0.002) final BW by 4% relative to steers receiving no DEX.  In the absence of growth 
implant, there was no effect (P ≥ 0.10) of DEX. 
Carcass measures 
 The effects of DEX injections and growth implant on carcass evaluation measures 
are shown in Table 5.3.  There was an interaction (P = 0.01) between treatments for 
slaughter weight.  In the presence of growth implant, DEX injections decreased (P < 
0.0001) slaughter weight by 4% as compared to steers given no DEX.  In the absence of 
growth implant, there was no effect (P ≥ 0.10).  Likewise, there was a tendency for an 
interaction (P = 0.06) between treatments for HCW.  Again, in the presence of growth 
implant, DEX injections decreased (P = 0.009) HCW by 3% relative to steers receiving 
no DEX.  However, there was no effect (P ≥ 0.10) of DEX in the absence of growth 
implant.  There was also an interaction (P = 0.04) between DEX injections and growth 
implant for dressing percentage.  In this case, DEX injections increased (P = 0.02) 
dressing percentage by almost 1 percentage point in the presence of implant compared to 
steers receiving no DEX.  However, in the absence of implant, there was no effect (P ≥ 
0.10) of DEX.  Growth implant increased (P = 0.02) longissimus dorsi area by 3% over 
non-implanted steers.  There was a tendency for an interaction (P = 0.06) of treatments on 
the percentage of ether extract in the longissimus dorsi muscle.  In the absence of DEX, 
steers receiving growth implant had a lower percentage of fat in the longissimus dorsi 
compared to those with no implant.  There was no effect (P ≥ 0.10) of growth implant in 
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the presence of DEX.  However, upon visual appraisal of the longissimus dorsi, there was 
no effect (P ≥ 0.10) of treatment on marbling score.  Also, there was no effect (P ≥ 0.10) 
of treatment on longissimus fat cover, yield grade or quality grade.  However, growth 
implant decreased (P = 0.02) the percentage of KPH fat relative to non-implanted steers. 
Organ and alimentary fat mass 
 The effects of DEX injections and growth implant on organ and alimentary fat 
mass are shown in Table 5.4.  A tendency for an interaction between treatments was 
observed for total digestive tract (P = 0.08) and forestomach (P = 0.07) weights.  For both 
the total digestive tract (P = 0.02) and the forestomach complex (P = 0.03), weights were 
greater in the absence of DEX for steers receiving growth implant compared to no growth 
implant.  However, there was no effect (P ≥ 0.10) of growth implant in the presence of 
DEX.  While there was no effect (P > 0.1) of treatment on the weights of omasum + 
abomasum, SI or LI, there was an interaction (P = 0.03) between DEX injections and 
growth implant on rumen + reticulum weight.  In the presence of growth implant, DEX 
injections decreased (P = 0.04) rumen + reticulum weight by 9% compared to no DEX.  
In the absence of growth implant, there was no effect (P ≥ 0.10) of DEX.  For liver 
weight there was an interaction (P = 0.04) between treatments.  In the absence of implant, 
DEX injections increased (P = 0.005) liver weight by 13% relative to steers receiving no 
DEX, but there was no effect (P ≥ 0.10) of DEX injections in the presence of growth 
implant.  There were no effects (P > 0.09) of treatment on liver DM content.  However, 
there was a tendency (P = 0.09) for steers receiving DEX to have a lower percentage of 
fat in the liver compared to those steers receiving no DEX.  There were no effects (P > 
0.10) of treatment on pancreas weight.  However, there was an interaction (P = 0.03) 
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between treatments on the weight of alimentary tract fat.  In the absence of growth 
implant, there was a tendency (P = 0.08) for steers receiving DEX injections to have 
heavier alimentary tract fat weights compared to steers receiving no DEX.  In the 
presence of growth implant, there was no effect (P ≥ 0.10) of DEX.  This interaction for 
alimentary tract fat weight is partially explained by an interaction (P = 0.002) between 
DEX injections and growth implant on omental fat weight.  In the absence of growth 
implant, omental fat weights were greater (P = 0.01) for steers receiving DEX injections 
relative to steers receiving no DEX.  However, in the presence of implant, omental fat 
weight decreased (P = 0.04) for steers receiving DEX injections compared to steers 
receiving no DEX. 
Organ and alimentary fat mass as a percentage of EBW 
 The effects of DEX injections and growth implant on organ and alimentary fat 
mass as a percentage of EBW are shown in Table 5.5.  An interaction (P = 0.003) 
occurred for final empty body weight (EBW).  In the presence of growth implant, DEX 
injections decreased (P = 0.001) EBW by 4% compared to steers receiving no DEX.  In 
the absence of growth implant, there was no effect (P ≥ 0.10) of DEX.  There was no 
effect (P ≥ 0.1) of treatment on digestive tract, forestomach complex, rumen + reticulum, 
omasum + abomasum, small intestine or large intestine weights as a percentage of EBW.  
However, DEX injections increased liver (P = 0.01) and pancreatic (P = 0.05) weights as 
a percentage of EBW compared to steers receiving no DEX injections.  Similar to the 
interaction between treatments for alimentary fat mass, there was a tendency (P = 0.09) 
for an interaction for alimentary tract fat as a percentage of EBW.  Furthermore, there 
was an interaction (P = 0.006) between treatments for omental fat as a percentage of 
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EBW.  In the absence of implant, steers receiving DEX injections had a greater amount 
(P = 0.01) of omental fat as a percentage of EBW compared to steers receiving no DEX.  
However, there was no effect (P ≥ 0.10) of DEX injections in the presence of implant.  
Also, there was no effect of treatment on the amount of mesenteric fat as a percentage of 
EBW. 
Whole blood glucose concentrations in Exp. 3 
 The effects of DEX injections and growth implant on the concentrations of 
glucose in whole blood over the course of Exp. 3 are shown in Figure 5.1.  There was no 
effect (P ≥ 0.1) of treatment on whole blood glucose concentrations throughout the 
experiment.  However, whole blood glucose concentrations in all steers responded 
quadratically (P = 0.002) relative to day of the experiment. 
Experiment 4 
Growth performance 
The effects of DEX injections and growth implant on BW gain, DMI and 
efficiency of gain for Exp. 4 are shown in Table 5.6.  There were no interactions between 
treatments for DMI, ADG, efficiency of gain or final BW over 112 d.  Also, over the 
course of the entire experiment, there was no effect (P ≥ 0.10) of treatment on DMI.  
However, in the final period of the study, growth implant tended to increase (P = 0.08) 
DMI by 5% relative to non-implanted steers and DEX injections tended (P = 0.06) to 
decrease DMI by 5% compared to steers receiving no DEX.  Over 112 d, growth implant 
increased ADG (P = 0.004) and efficiency of gain (P=0.05)13% over non-implanted 
steers.  For implanted steers, the overall improvements in body weight gain and 
efficiency are reflective of increased ADG and efficiency in Periods 1 and 3 of the 
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experiment.  In Period 1, growth implant tended to increase (P ≤ 0.07) ADG by 11% and 
efficiency of gain by 10% relative to steers receiving no implant.  In Period 3, these 
improvements (P ≤ 0.02) were 29% and 25% for ADG and efficiency of gain, 
respectively. 
Unlike the improvement in ADG for implanted steers, DEX decreased (P = 0.007) 
ADG by 10% compared to steers receiving no DEX injections over the entire experiment.  
This lower ADG was largely due to a 21 % decrease (P = 0.005) in ADG for DEX 
relative to non-DEX injected steers during Period 2.  There was no effect (P ≥ 0.10) of 
DEX injections on efficiency of gain over 112 d.  However, in Period 2, efficiency was 
decreased (P = 0.001) by 18% for steers receiving DEX compared to no DEX.  Regarding 
final BW, growth implant increased (P = 0.004) weight by 4% relative to non-implanted 
steers and DEX injections decreased (P = 0.01) weight by 3% compared to steers 
receiving no DEX. 
Carcass measures 
 There were no interactions (P ≥ 0.10) between treatments for any of the measures 
of carcass quality (Table 5.7).  Growth implant increased (P = 0.0001) HCW by 5% 
compared to steers receiving no growth implant; however, administration of DEX 
decreased (P = 0.0007) HCW by 4% relative to steers receiving no DEX.  Likewise, 
steers receiving growth implant had larger (P 0.02) longissimus dorsi muscle areas 
compared to steers with no implant.  On the other hand, implanted steers tended (P = 
0.11) to have slightly less KPH fat than non-implanted steers.  There were no effects (P ≥ 
0.10) of treatment on dressing percentage, percentage of fat in the longissimus dorsi 
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muscle as measured by ether extract, longissimus dorsi fat cover, marbling, yield grade or 
quality grade. 
Organ and alimentary fat mass 
 The effects of DEX injections and growth implant on organ and alimentary fat 
mass are shown in Table 5.8.  The spleen weights of steers given DEX injections were 
found to weight 21% less (P = 0.0006) than steers receiving no DEX.  Conversely, the 
heart weights of implanted steers tended to weigh 6% more (P = 0.09) than non-
implanted steers.  There were no effects (P ≥ 0.10) of treatment on kidney or lung 
weights.  Total digestive tract weights of the steers receiving growth implant were 
heavier (P = 0.01) relative to the steers receiving no growth implant.  Forestomach 
weights tended to be 9.5% heavier (P = 0.10) for implanted compared to non-implanted 
steers.  The weights of the rumen + reticulum were 13% greater (P = 0.02) for implanted 
compared to non-implanted steers.  While there was no effect (P > 0.1) of treatment on 
the weight of the omasum, there tended to be an interaction (P = 0.09) between DEX 
injections and growth implant on the weight of the abomasum.  In the absence of DEX, 
implanted steers tended (P = 0.09) to have heavier abomasum weights relative to non-
implanted steers.  As with the rumen + reticulum weights, implanted steers had 13% and 
9% heavier (P ≤ 0.02) SI and LI compared with steers receiving no implant, respectively.  
On the other hand, steers receiving DEX injections had SI that weighed 11% less (P = 
0.002) and LI that tended (P = 0.10) to weigh 6% less than those receiving no DEX.  
Regarding liver weight, implanted steers also had heavier (P = 0.0004) liver compared to 
non-implanted steers.  Steers receiving DEX had livers that weighed 8% less (P = 0.03) 
that steers receiving no DEX.  There were no effects of treatment on the percentage of 
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DM or EE in the liver.  Also, pancreas weight tended (P = 0.06) to be greater for steers 
receiving implant relative to no implant.  There were no effects (P ≥ 0.10) of treatment on 
the weight of alimentary tract fat.   
Organ and alimentary fat mass as a percentage of EBW 
 The effects of DEX injections and growth implant on organ and alimentary fat 
mass as a percentage of EBW are shown in Table 5.9.  Final EBW was 7% greater (P = 
0.001) for implanted compared to non-implanted steers.  However, DEX injections 
decreased (P = 0.02) final EBW by 5% relative to steers receiving no DEX.  Similar to 
the results on a wet tissue weight basis, spleen weight was lower (P = 0.005) as a 
percentage of EBW for steers treated with DEX compared to no DEX.  However, heart 
weight was greater (P = 0.03) for steers receiving DEX relative to those given no DEX.  
On the other hand, implanted steers tended (P = 0.10) to have lighter kidney weights and 
the lungs weighed less (P = 0.02) as a percentage of EBW compared to non-implanted 
steers.  There was no effect (P ≥ 0.1) of treatment on digestive tract, forestomach 
complex, rumen + reticulum, omasum + abomasum, or large intestine weights as a 
percentage of EBW.  However, both DEX and growth implant had an effect on small 
intestine weight as a percentage of EBW.  Steers with growth implant had heavier (P = 
0.05) SI and steers receiving DEX had SI that weighed less (P = 0.02) on an EBW basis 
relative to those animals receiving no growth implant or no DEX, respectively.  Also, 
implanted steers had heavier (P = 0.006) livers as a percentage of EBW compared to non-
implanted steers.  Lastly, steers receiving DEX tended (P = 0.06) to have heavier 
pancreas weights relative to steers receiving no DEX.  There was no effect of treatment 
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on the amount of total alimentary tract fat, omental fat or mesenteric fat as a percentage 
of EBW. 
DISCUSSION 
 While a plethora of information exists regarding the effects of DEX on adipose 
depots in humans and rats, there is a lack of research regarding these effects in ruminants.  
Because DEX has the ability to induce an insulin resistant state in the adipose depots of 
humans and rats, glucose begins to be deposited as intramuscular fat in muscle (Asensio 
et al., 2004; Hegarty et al., 2003).  This phenomenon has been well-documented in 
humans, but has not been proven to occur in ruminants (Asensio et al., 2004; Hegarty et 
al., 2003).  However, a study by Brethour (1972) suggested that steers receiving IM 
injections of DEX 90, 76 or 33 d pre-slaughter improved marbling from 8% Choice to 
30% Choice, thus improving the USDA quality grade.  The additional treatment of 
growth implant would determine if the opposing effects of increasing lean tissue 
deposition would interact with the effects of increasing fat deposition within muscle and 
primary fat depots.  Furthermore, few studies have examined the effects of growth 
implant on omental and mesenteric fat, as well as organ weights in beef cattle.  Based on 
the research by Brethour (1972) and the knowledge that DEX causes a shift in fat 
deposition from adipose to non-adipose tissue (muscle) in humans and rats, we conducted 
the current experiments to assess the effects of DEX injections in the presence and 
absence of growth implant on growth performance, carcass quality, omental and 
mesenteric fat depots, and organ weights.  We hypothesized that DEX injections would 
increase marbling and the amount of omental and mesenteric fat; however, we 
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hypothesized that the addition of growth implant may mitigate the increase in marbling, 
omental and mesenteric fat.  
 
Growth performance 
 In Exp. 3, overall DMI increased by 4% for steers implanted with Revalor-S® 
compared to non-implanted steers, while there was no change in overall DMI for Exp. 4.  
The increase in DMI for Exp. 3 was due to increases in DMI for Periods 1 & 3, in which 
there was either an increase or tendency for an increase in DMI.  The reason as to the 
increase in DMI for Exp. 3 is unclear, as most studies have shown no changes in DMI for 
steers implanted with Revalor-S® (Samber et al., 1996; Foutz et al., 1997).  In an 
experiment by Samber et al. (1996), steers were implanted with Revalor-S® on d 30 and 
130 of a 150-d study and showed no change in DMI compared to non-implanted steers.  
Likewise, a study by Foutz et al. (1997) using steers implanted or not implanted with 
Revalor-S® on d 1 showed no differences in DMI over 119 or 126 d.  Overall, it was not 
expected that DMI would increase in steers implanted with Revalor-S®, as the goal of 
anabolic implants is to increase feed efficiency; i.e., increase protein accretion with no 
increase in feed intake.  Regarding the effects of DEX on DMI, there were no changes in 
DMI for steers implanted with DEX in Exp. 3 or 4.  A study by Adams and Sanders 
(1992) showed an increase in DMI over a 10-d period for sheep injected with DEX. 
Another study by Carroll et al. (1963) showed that steers injected three times per week 
with one gram of cortisone acetate consumed more feed over the course of a 9 week 
experiment.  In the current experiment, it is possible that because the animals were 
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receiving only one injection of DEX every 28 d, any effects of DEX on DMI were short-
term; i.e., they were only manifested for a few days following injection.   
 It was expected that implant would increase ADG and while this occurred for 
implant alone in Exp. 4, there was an interaction between implant and DEX for Exp. 3.  
In the presence of growth implant, DEX decreased ADG by 10% compared to steers 
receiving no DEX.  This interaction also translated to DEX decreasing slaughter weight 
and HCW by 4 and 3%, respectively, in the presence of growth implant.  Dexamethasone 
also decreased ADG, slaughter weight and HCW in Exp. 4.  The reason for these 
decreases in ADG is unclear; however, they may be attributed to decreased protein 
deposition or increased protein catabolism, or increased heat production.  The effect of 
DEX decreasing HCW lends support to the theory that protein deposition decreased, or 
protein catabolism or heat production increased.  Glucocorticoids such as DEX are 
known to inhibit protein tissue deposition (Hart 1983).  In a study by Carroll et al. (1963), 
steers exhibited less protein deposition during a 9-week study in which they were injected 
subcutaneously three times per week with one gram of cortisone acetate.  Furthermore, 
glucocorticoids stimulate muscle breakdown by causing the release of amino acids to fuel 
glucose synthesis (McDowell 1983).  Another study showed seven-day-old piglets 
receiving 0.5 mg/kg BW/d oral DEX for 15 d to exhibit a lower whole body percent lean 
mass, which was attributed to protein catabolism (Weiler et al., 1997).  A study by 
Brillon et al. (1995) evaluated the effect of infusing hydrocortisone overnight into healthy 
adults along with labeled amino acids to measure amino acid kinetics.  They also used 
indirect calorimetry techniques to calculate resting energy expenditure.  They found that 
hypercortisolemia increased protein catabolism by 5-20% and resting energy expenditure 
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increased 9-15%.  It is possible that an inhibition of tissue deposition, muscle catabolism 
and energy expenditure via increased heat production cooperated to decrease ADG and 
ultimately HCW for steers receiving DEX. 
 An increase in ADG of 13% occurred for implant compared to non-implanted 
steers in Exp. 4, which was expected.  Efficiency of BW gain also increased by 16% and 
13%, respectively for implanted vs. non-implanted steers in Exp. 3 and 4.  Studies have 
shown trenbolone acetate + estradiol implants to increase both ADG and efficiency of 
gain for finishing beef steers. (Foutz et al., 1997; Samber et al., 1996; Scheffler et al., 
2003). Foutz et al. (1997) used 140 crossbred steers (353 kg) receiving either no implant, 
Synovex-S®, Revalor-S®, Finaplix-S, or Finaplix-S+ reimplant on d 58.  Steers were fed 
for either 119 or 126 d and then slaughtered.  Average daily gain and feed efficiency 
were increased by 6.1 and 7.5%, respectively, for steers receiving the treatments with 
trenbolone acetate compared to the steers receiving no trenbolone acetate.  In another 
experiment by Samber et al. (1996), 560 crossbred steers (286 kg) received no implant, 
Ralgro® or Revalor-S® implants on d 0.  These steers were reimplanted with either 
Synovex-S® or Revalor-S® on d 60 and 130 or d 75 and 150.  Two groups of steers 
received Revalor-S® or Synovex-S® implants on d 30 and both groups were reimplanted 
with Revalor-S® on d 130.  All steers were fed for 212 d.  Average daily gain and feed 
efficiency for steers receiving the Revalor-S® implants on d 30 and 130 increased by 15 
and 10%, respectively, compared to the non-implanted steers. The results of the current 
experiments agree with these results.  
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Carcass quality 
 Overall, the carcass quality data showed that independent of treatment, the steers 
in Exp. 4 ended the experiment with less fat as compared to the steers in Exp. 3.  In 
comparison, there were decreases of 20% in longissimus fat cover, 1.5% in KPH fat, 14% 
in marbling score, 40% in EE% of the LD muscle, 24% in yield grade and 18% in quality 
grade.  Additionally, there was a 14% decrease in the amount of alimentary tract fat for 
steers in Exp. 4 compared to steers in Exp. 3.  These results were surprising, considering 
that the steers in both experiments finished with similar slaughter weights (558 kg in Exp. 
3 and 553 kg in Exp. 4), demonstrating that all steers finished at similar stages of 
maturity.  Treatments also affected the steers in each experiment differently, with DEX 
mitigating the effects of growth implant in Exp. 3 and no interaction of treatments in Exp. 
4. 
In Exp. 3, steers receiving DEX in the presence of implant had higher dressing 
percentages as compared to steers receiving no DEX with implant.  This result has 
practical implications in that it indicates that while the steers receiving DEX and growth 
implant were smaller steers in terms of slaughter weight and HCW, they had a greater 
percentage of “usable” carcass compared to steers receiving no DEX with implant.  In 
Exp. 4 there was no effect of treatment on dressing percentage.  In both experiments, 
there was an increase in longissimus dorsi (LD) area of 3.7 and 3.8%, respectively, for 
implanted compared to non-implanted steers, which was expected.  These results are 
similar to other studies in which Revalor-S® has been used.  In studies by Foutz et al. 
(1997; 1990), implanted steers had larger LD areas.  It would be expected that implants 
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would increase LD area, as they are stimulating an increase in the deposition of lean 
tissue. 
 In Exp. 3, implanted steers had less KPH fat.  These results are similar to other 
studies in which Revalor-S® has been used.  In the studies by Foutz et al. (1997; 1990), 
implanted steers had no change in the amount of KPH fat.  As mentioned previously, 
there was no effect of treatment in either experiment on longissimus fat cover, marbling, 
yield grade or quality grade.  The lack of effect of Revalor-S® on longissimus fat cover 
and marbling agrees with the findings of Foutz et al. (1997) and Samber et al. (1996).  
Longissimus fat cover, KPH fat and marbling are some of the most important factors in 
determining yield grade; therefore, if these parameters are unaffected by treatment, it is 
unlikely that yield grade will be affected.  Quality grade is a more subjective evaluation 
based mainly on the amount of intramuscular fat, or marbling, within the longissimus 
dorsi muscle.  In the current experiments, both an objective determination of the ether 
extract percentage and a subjective score of marbling were measured in the longissimus 
dorsi muscle.  There was no effect of implant on marbling scores, leading to no change in 
quality grade.  However, in Exp. 3, there tended to be an interaction between implant and 
DEX for ether extract percentage in the longissimus dorsi muscle, which was explained 
as an decrease in the amount of ether extract for implanted steers in the absence of DEX.  
The lack of a corresponding interaction for marbling score suggests that this method is 
not as sensitive to intramuscular fat differences as an ether extract determination. 
Additionally, these results show that DEX increased intramuscular fat despite the 
opposing effects of implant, which agrees with the results of Brethour (1972), in which 
DEX improved marbling scores. 
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 Based on previous research, it was anticipated that DEX would increase 
longissimus fat cover, KPH fat and marbling, thereby increasing yield grade and 
improving quality grade.  In experiments with steers and lambs in which cortisone acetate 
was injected, administered intraruminally or as an implant, carcass fatness in lambs was 
generally increased (Clegg and Spurlock, 1960; Spurlock and Clegg, 1962; Carroll et al., 
1963).  Brethour (1972) showed that steers receiving IM injections of DEX 90, 76 or 33 d 
pre-slaughter increased marbling from 8% Choice to 30% Choice, thus improving the 
USDA quality grade.  The steers in the current experiments were injected with DEX 
every 28 d throughout both experiments; therefore, it was expected that the increased 
frequency of injections would improve quality grade.  Dexamethasone has temporal 
effects on circulating glucose concentrations, as demonstrated by our preliminary data in 
which whole blood glucose concentrations more than doubled for 2 d following IM 
injections with either 10 or 20 mg of DEX (data not shown).  Along with an increase in 
circulating blood glucose, research also shows DEX to stimulate lipolysis in rats, thus 
increasing circulating free fatty acids (Krotkiewski et al., 1970).  It was hypothesized that 
these changes may cause a temporary redistribution of fat from primary to secondary fat 
depots, thus increasing intramuscular fat in the LD muscle.  It was also hypothesized that 
over the course of the experiments, DEX may increase fat deposition in primary fat 
depots such as longissimus fat cover and KPH fat.  However, these increases were not 
observed for steers receiving DEX in either experiment. 
Organ and fat mass                                                                                                                                                                       
 The effects of maternal DEX on the weight of the service organs (spleen, kidneys, 
heart, lungs) has been evaluated extensively in fetal rats and to a lesser extent, in sheep 
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(Frank et al., 1985; Jensen et al., 2002).  However, these measurements have not been 
reported in finished beef cattle receiving DEX injections prior to slaughter.  While 
individual spleen, kidney, heart and lung weights were not recorded for Exp. 3, they were 
recorded for Exp. 4.  Dexamethasone decreased spleen weight by 21% on a wet tissue 
mass basis compared to steers receiving no DEX; this difference remained significant 
when expressed as a percentage of EBW.  This agrees with research in rats treated with 2 
mg/kg BW/d DEX during 5 consecutive d (Orzechowski et al., 2000).  Spleen wet weight 
expressed as a percentage of BW decreased by 65%.  The decrease in spleen weight may 
be due to a depression in immune function by DEX.  A study by Miller et al. (1991) in 
which rats were administered varying concentrations of DEX showed decreased spleen 
weights along with decreases in immune function.  There was no effect of implant on 
spleen weight, which disagrees with research by Hutcheson et al. (1997).  Twenty-four 
genetically identical Brangus steers were either not implanted, implanted with Synovex-
S®, Finaplix-S or Revalor-S® and slaughtered after 112 d for determination of visceral 
organ mass.  As a percentage of EBW, the spleens were found to weigh more for the 
steers receiving Revalor-S® as compared to steers receiving no implant. 
 While there were no effects of treatment on kidney, heart or lung wet tissue 
weights, there was an effect of DEX on heart weight and an effect of growth implant on 
lung weight when expressed as a percentage of EBW in Exp. 4.  Dexamethasone 
increased heart weight, which agrees with an experiment by Jensen et al. (2002).  In this 
experiment, pregnant ewes were infused with 80 mg/d hydrocortisone for 10 d beginning 
at 119 d gestation.  Maternal cortisol infusion increased fetal heart weight by 15% 
relative to body weight.  It is unknown whether an increase in heart weight may be due to 
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hypertrophy or hyperplasia in the current experiment.  In the current experiment, lung 
weight decreased as a percentage of EBW for steers receiving growth implant compared 
to steers receiving no implant.  In the study by Hutcheson et al. (1997), heart, lungs and 
trachea were weighed together as “pluck,” and there was no effect of treatment on the 
weight of the pluck.  While there was no effect of DEX on lung weight in the current 
experiment, other research in which pregnant rats received 0.2 mg/kg BW of DEX at 48 
and 24 h prior to parturition showed the pups to have lower lung weights at birth 
compared to pups born to mothers receiving no DEX (Frank et al., 1985).   
There were no effects of implant on kidney weight in the current experiment, 
which agrees with the study by Hutcheson et al. (1997) in which none of the implant 
regimes affected kidney weight as a percentage of EBW.  This also agrees with a study 
by McClure et al. (2000) in which lambs were implanted with trenbolone acetate + 
estradiol benzoate or non-implanted and slaughter at a final BW of 47-50 kg.  Organs and 
viscera were weighed at slaughter and kidney wet tissue weights were not different 
between implanted and non-implanted lambs.  Dexamethasone also failed to affect 
kidney weight in the current experiment, which agrees with the study by Jensen et al. 
(2002), in which maternal hydrocortisone infusions did not affect kidney weights of the 
pups. 
 In Exp. 3, there were interactions between treatments to affect the wet tissue 
weights of the digestive tract, forestomach complex and rumen + reticulum.  However, 
these interactions did not occur when the weights of these tissues were expressed as a 
percentage of EBW.  In Exp. 4, there was a 7% decrease in digestive tract weight for 
steers receiving DEX and an 11% increase in digestive tract weight for steers receiving 
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implant. The overall increase in digestive tract weight for implanted steers was due to a 
13% increase in rumen + reticulum weight for these animals.  However, these changes 
did not translate to changes when expressed as a percentage of EBW.  These results agree 
with research by Gill et al. (1987) in which young calves implanted with estradiol 17-β 
had no change in total GIT weights compared to non-implanted calves.  However, these 
results disagree with the study by Hutcheson et al. (1997) which showed the steers 
receiving Revalor-S® to have decreased GIT weights when expressed as a percentage of 
EBW. 
 There was no effect of treatment on SI or LI wet tissue weights alone or expressed 
as a percentage of EBW in Exp. 3; however, in Exp. 4, DEX decreased SI wet tissue 
weight by 11%, which translated to a decrease as a percentage of EBW.  This decrease in 
SI tissue weight agrees with research in rats which has shown similar results (Kelly and 
Goldspink, 1982).  These researchers used male rats injected with saline or 2.5 mg 
DEX/kg BW/d for 5 d, after which they were injected with phenylalanine to assess 
muscle metabolism and then killed.  Dexamethasone caused atrophy of the smooth 
muscle of the SI and a 10% decrease in the non-stretched length of the SI.  It is possible 
that muscle atrophy and decreased length may have contributed to the decreased weight 
of the SI of the steers treated with DEX in our experiment.   
In Exp. 4, it was determined that growth implant increased SI and LI wet tissue 
weights by 13 and 10%, respectively; however, only SI wet tissue increased as a 
percentage of EBW due to growth implant.  This disagrees with the experiment by 
McClure et al. (2000) in which there was no change in SI wet weight between implanted 
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and non-implanted lambs; however, there was an increase in LI wet weight of 12% for 
implanted compared to non-implanted lambs, which agrees with our experiment. 
In Exp. 3, there was an interaction between treatments for liver wet tissue 
weights, which was due to an increase in liver weight for steers receiving DEX in the 
absence of implant.  This interaction did not occur when liver weight was expressed as a 
percentage of EBW; however, steers receiving DEX alone had greater liver weights as a 
percentage of EBW.  These results agree with the study by Jensen et al. (2002) in which 
fetal sheep exposed to maternal cortisol infusions had increased liver weights as a 
percentage of EBW.  In Exp. 4, there was no interaction of treatments to affect liver wet 
tissue weight, but DEX alone decreased and implant increased liver wet weight.  
However, when expressed as a function of EBW, steers receiving implant had greater 
liver weights compared to non-implanted steers.  These results agree with the experiment 
by Hutcheson et al. (1997), in which steers implanted with Revalor-S® had increased 
liver weights as a percentage of EBW compared to non-implanted steers.  There was no 
effect of treatment on the ether extract percentage of the liver in Exp. 4; however, in Exp. 
3, DEX tended to decrease the ether extract percentage of the liver.  This tendency for a 
decrease in the ether extract percentage for the steers receiving DEX is a function of the 
increase in liver weight for the steers given DEX in the absence of implant.  The amount 
of fat present in the livers of steers receiving no DEX is calculated to be 100.2 g and the 
amount of fat present in the livers of steers receiving DEX is 93.4 g; therefore, the 
relationship is clear that the decreased ether extract percentage is a function of increased 
liver weight and not due to a substantial difference in the amount of fat present in the 
liver of DEX-treated steers. 
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In Exp. 3, there was no effect of treatment on pancreas wet tissue weight; 
however, when expressed as a percentage of EBW, DEX increased pancreas weight.  In 
Exp. 4, steers receiving implant tended to have increased pancreas wet tissue weights, but 
this effect did not occur for implanted steers when expressed as a percentage of EBW.  
However, DEX tended to increase pancreas weights in Exp. 4 when expressed as a 
percentage of EBW.  While the effect of DEX on pancreas was significant only when 
weights were expressed as a percentage of EBW.  Research in rats has reported the 
administration of DEX increases pancreas wet tissue weights.  A study by Sugiyama et al. 
(2005) used male Wistar rats and examined the effects of DEX on caerulein-induced 
acute pancreatitis.  Dexamethasone was administered (3 mg/kg BW) prior to induction of 
pancreatitis and pancreas weights were increased.  While it is unclear why DEX 
increased pancreas weight, research performed in vitro has investigated the role of 
glucocorticoids in pancreas development using rat and mice embryonic pancreas cells 
(Gesina et al., 2004).  These cells were treated with or without 100nmol/L DEX.  It was 
found that DEX decreased the number of differentiated β-cells and increased the 
differentiated acinar cell area.  In the current experiments, it could be possible that DEX 
increases pancreas weight by increasing the number or size of acinar cells in the 
pancreas. 
 While there were no effects of treatment on alimentary tract fat, omental or 
mesenteric fat wet tissue weights, and no effects on these weights expressed as a 
percentage of EBW in Exp. 4, there were interactions of treatments in Exp. 3 to affect 
both alimentary tract fat and omental fat weights.  The interaction affecting alimentary 
tract fat wet tissue weight was due to an increase in fat for steers receiving DEX in the 
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absence of implant; however, there was only a tendency for this interaction to occur when 
expressed as a percentage of EBW.  Omental fat was a component of total alimentary 
tract fat and a similar interaction of treatments occurred to affect this depot.  In the 
absence of implant, steers receiving DEX had more omental fat on both a wet tissue basis 
and as a percentage of EBW.  However, the interaction was also caused by a decrease in 
omental fat on a wet tissue basis and as a percentage of EBW for steers receiving DEX in 
the presence of implant.  This response by omental fat decreasing in the presence of 
implant was unexpected in this experiment.  Research in which omental fat has been 
quantified after increased circulating cortisol levels has shown an increase in the amount 
of omental fat (Weber-Hamann et al., 2002).  It was unknown if ruminants would 
respond to a single injection of DEX every 28 d with changes in the omental fat depots, 
but it was hypothesized that the injections may increase the amount of fat in the omental 
depot if the animals were in an insulin-resistant state.  While increased omental adiposity 
has been implicated in the metabolic syndrome (glucose intolerance, hyperinsulinemia, 
hyperlipidemia) and thus, a feature of Type II diabetes in humans, it is unknown whether 
increased omental fat is a result or cause of diabetes (Kissebah et al., 1982; Evans et al., 
1984; Montague and O’Rahilly, 2000).  From the current data, it appears that the addition 
of implant to the DEX treatment mitigates the increase in omental fat; however, the 
mechanism of how this occurs remains to be elucidated. 
Whole blood glucose concentrations 
 Whole blood glucose concentrations were measured on d 0, 28, 56 and 84 in Exp. 
3 to ascertain if the steers receiving DEX injections became insulin resistant over the 
course of the experiment.  There was no effect of treatment on whole blood glucose 
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concentrations, but there was a quadratic effect of day.  From the preliminary experiment 
we conducted of injecting 3 steers with either 10 or 20 mg of DEX and collecting blood 
samples for 2 days post-injection, we concluded that whole blood glucose concentrations 
more than doubled and remained elevated for approximately 36 h after injection.  
Glucose concentrations then slowly returned to baseline concentrations by 48 h post-
injection.  In the current experiment, we hypothesized that over the course of 84 d, the 
DEX injections may cause insulin resistance and thus, possibly increase baseline 
concentrations of blood glucose by the conclusion of the experiment.  However, this 
increase did not occur.  Rather, over the course of the experiment, we observed very 
minor increases in baseline glucose concentrations for all steers by d 28, followed by 
minor decreases until d 84.  It is unclear why this effect occurred, but the concentrations 
only changed by 1-2 tenths of a milligram; while statistically significant, these changes 
cannot be considered biologically significant. 
 In general, our findings demonstrated in Experiment 3 that DEX mitigated the 
effects of growth implant on some of the growth & performance data, while there was 
also an interaction between treatments for some of the carcass quality and organ and fat 
mass data.  This was not the case in Experiment 4, as DEX and growth implant did not 
interact to affect any of our measurements.  However, DEX clearly decreased growth and 
weights of some organs.  
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Table 5.1  Experimental diets  
   
Ingredient, % DM Exp. 3 Exp.4 
High moisture corn          80.00               0.00 
Cracked corn            0.00             80.00 
Alfalfa haylage          10.00             10.00 
Ground corn            6.90               4.39 
Soybean meal            1.23               3.48 
Urea            0.46               0.00 
Limestone            0.60               1.30 
Trace mineralized salt1            0.50               0.51 
Choice white grease            0.26               0.27 
Vitamins A,D,E2            0.02               0.02 
Rumensin-80            0.02               0.02 
Tylan-40            0.008               0.008 
1 92.00% NaCl, 5,500 ppm Zn, 4,790 ppm Mn, 1,835 ppm Cu, 
9,275 ppm Fe, 115 ppm I, 65 ppm Co, 18 ppm Se  
2 8,800 IU/g vitamin A, 1,760 IU/g vitamin D, 1.1 IU/g vitamin E  
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Chapter 6 
General Discussion 
 
   In finishing beef cattle, a goal of producers is to maximize lean tissue growth as 
efficiently as possible.  This goal is generally accomplished through use of anabolic 
growth implants containing various combinations of estrogen, progesterone and 
trenbolone acetate.  Historically, the drawback of using these growth implants has been a 
negative impact on marbling, or intramuscular fat content within the longissimus dorsi 
muscle.  The amount of marbling at slaughter determines the USDA quality grade 
assigned to the carcass, leading to a significant profit if the carcass grades “Choice.”  
Research has shown that growth implants have the potential to decrease the amount of 
marbling in finishing cattle, thus decreasing profit for producers.  Therefore, the addition 
of a compound to the finishing program of beef cattle to counteract the negative impact 
of growth implants on marbling may increase profit. 
The results of the current experiments provide greater understanding of the 
physiological effects of the adipogenic compounds, chlortetracycline and dexamethasone, 
on fat deposition in ruminants.  Furthermore, insight was gained regarding the interaction 
of these compounds with anabolic growth implants, which are routinely used in finishing 
beef cattle.  Chlortetracycline (CTC) has been shown in previous research with swine, 
lambs and cattle to improve carcass quality; however, in our experiments, we did not see 
a significant improvement in marbling or overall fatness of the finished steers.  While the 
reason for this lack of effect in these experiments is unclear, we discovered that CTC 
attenuated the positive effects of growth implant on lean tissue gain and efficiency of 
gain.  Furthermore, by evaluating the growth hormone (GH) and thyroid hormone status 
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of these cattle, we found that CTC may be causing the mitigation in lean tissue gain and 
efficiency of gain via attenuation of triiodothyronine response.  This suggests that CTC 
may be initiating effects on fat deposition by moderating the effects of thyroid hormones.  
We also gained new information in describing the time course response of GH and 
thyroid hormones over a typical finishing period for beef cattle implanted with growth 
implants.  In general, we found that finishing cattle have elevated circulating thyroid 
hormone concentrations and greater thyroid hormone responses to a releasing-hormone 
challenge.  As the use of subtherapeutic antibiotics becomes more unfavorable in 
production animals, the importance of discovering the mechanism of action of CTC 
regarding fat deposition becomes more imperative.  If this mechanism can be determined, 
it may be possible to manufacture only the part of the compound responsible for 
increasing fat deposition and administer this compound to finishing beef cattle to improve 
marbling. 
In the latter two experiments, we used dexamethasone (DEX) in conjunction with 
growth implants to study another possible mechanism for improving marbling in 
finishing cattle.  In humans and rodents, it has been shown in numerous experiments that 
DEX induces both short-term and long-term insulin resistance, which in turn has been 
shown to cause fat deposition to shift from adipose to non-adipose tissue (muscle).  
Previous research had shown DEX injections up to 90 d prior to slaughter in finishing 
beef cattle improved carcass quality grade via increases in marbling.  We hypothesized 
that these increases may be due to insulin resistance caused by DEX; thus the hypothesis 
in the current experiments was that injections of DEX every 28 d prior to slaughter would 
increase marbling, increase fat in omental and alimentary fat depots and decrease weight 
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of service organs.  These injections were also administered in conjunction with growth 
implants to evaluate the effects on lean tissue gain and fat deposition both in 
intramuscular fat and other fat depots such as omental and alimentary fat.  In general, we 
found that while DEX did not improve marbling, as measured by either subjective scores 
or objective total crude fat determination in the longissimus dorsi muscle, DEX 
attenuated both the increased ADG and final BW for steers also receiving growth 
implant.  Interestingly, we also saw increases in omental fat weights without implant, but 
decreases in omental fat with implant.  New information gained from these experiments 
included characterization of the effects of both DEX and growth implant on weights of 
the parts of the GIT, fat depots and service organs.  To date there has been little published 
research regarding the effects of growth implants, and no published research regarding 
the effects of DEX, on the weights of these tissues in finishing cattle.  Finally, while 
preliminary research in 3 steers administered DEX injections demonstrated a two-fold 
increase in circulating blood glucose concentrations for 2 d, long-term effects on 
circulating blood glucose concentrations were not observed.  To sustain an increase in 
blood glucose concentrations, it is likely necessary to give more frequent DEX injections, 
such as every 2-3 days.  While we did not see this increase in blood glucose, we 
hypothesized that DEX injections every 28 d may have long-term effects on the 
expression of genes involved in lipogenesis, lipolysis and glucose metabolism, i.e., fat 
deposition may still be shifted from primary to secondary fat depots within muscle.  
While we did not observe these changes in the current experiments, it is worthwhile to 
modify the research methods and continue to study the possibility of inducing insulin 
resistance in ruminants and observing possible effects on marbling.  Furthermore, 
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determination of the mechanisms and metabolic pathways involved in the control of fat 
deposition in ruminants also remain unclear; therefore, more research is necessary to 
elucidate these pathways as well. 
Because the producer is paid based on the quality grade of the carcass and quality 
grade is determined by the amount of marbling, it is necessary to continue research 
regarding ways to improve marbling in cattle administered growth implants.  We have 
studied two compounds in these experiments aimed at improving marbling and have only 
begun to understand how these compounds manipulate fat deposition and also how they 
interact with growth implants. 
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